Pendred Syndrome

Mendelian MONDO:0010134 Pathograph 29 Show in embeddings browser Hearing loss disorder

Pendred syndrome is one protein failing in two epithelia, and almost everything clinically distinctive about it follows from that. Pendrin, encoded by SLC26A4, is an apical anion exchanger that moves chloride, bicarbonate and iodide. In the inner ear it secretes bicarbonate into endolymph; in the thyroid it sits at the apical membrane of the follicular cell facing the lumen, where iodide has to cross to be organified. Losing it therefore gives sensorineural hearing loss with an enlarged vestibular aqueduct and, separately, a partial iodide organification defect with goitre. The inner-ear arm is developmental and time-limited, which is the fact that organises the rest of the entry. Conditional restoration of Slc26a4 in mice showed that pendrin is required across a narrow perinatal interval, and that its absence in that interval acidifies endolymph, collapses the endocochlear potential and leaves the animal unable to acquire normal hearing. So the injury is not a slow degeneration that could be arrested at any point - it is a developmental failure with a closing window, and that is what any disease-modifying therapy has to reach. The second thing worth stating plainly is that this is the syndromic end of a spectrum, not a separate disease from DFNB4. The same biallelic SLC26A4 genotypes produce hearing loss with an organification defect in some people and without one in others, and iodine intake modifies which. The thyroid phenotype is what names the syndrome; it is not what causes the deafness.

Ask OpenScientist

Ask a research question about Pendred Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
7
Phenotypes
3
Gaps
29
Pathograph
1
Genes
2
Variants
8
Medical Actions
2
Subtypes
2
Models
12
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
Biallelic SLC26A4 variants. The allelic accounting is unusually well characterised and is curated in the genetic section, because a substantial minority of patients with the same inner-ear phenotype carry only one detectable coding allele or none.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:20301640 SUPPORT Other
"The diagnosis of SLC26A4-SNHL is established in a proband with suggestive findings and biallelic pathogenic variants in SLC26A4 identified by molecular genetic testing."
GeneReviews states the biallelic requirement as the diagnostic criterion.
PMID:20301640 SUPPORT Other
"If both parents are known to be heterozygous for an SLC26A4 pathogenic variant, each sib of the proband has at conception a 25% chance of having SLC26A4-SNHL, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the pathogenic variants."
The transmission risk, which is the fact a family actually needs from the inheritance mode. Note the conditional the sentence opens with - it holds once both parents are established as carriers, which the entry's own account of CEVA and deep-intronic alleles shows is not automatic.
◆

Subtypes

2
Pendred syndrome, with thyroid involvement
The syndromic phenotype: SLC26A4 hearing loss plus a demonstrable iodide organification defect, usually with goitre. Recognised more often where salt is not iodised.
DFNB4, nonsyndromic SLC26A4 hearing loss with EVA
The same inner-ear disease without demonstrable thyroid involvement, also called nonsyndromic enlargement of the vestibular aqueduct. Curated as a subtype rather than as a separate entry because the gene, the inner-ear mechanism and the allelic spectrum are the same; it is the organification defect that separates the two labels.
Show evidence (1 reference)
PMID:34345941 SUPPORT Other
"A thyroid iodine organification defect can lead to multinodular goiter and distinguishes Pendred syndrome from DFNB4."
States exactly what separates the two labels, and by implication what does not.
?

Discussions and Knowledge Gaps

3
Does the postnatal therapeutic window demonstrated in mice exist in humans, and when does it close?
HUMAN MODEL MISMATCH pendred_human_therapeutic_window_unknown
Attached to
animal_models#Doxycycline-inducible Slc26a4 transgenic mouse on the Slc26a4-null background treatments#AAV SLC26A4 Gene Replacement (Investigational)
This is the question on which every disease-modifying therapy for Pendred syndrome depends, and the mouse data point two ways at once. The conditional model established a narrow interval, E16.5 to P2, in which pendrin has to be present for hearing to be acquired. In mouse developmental terms much of that is prenatal, and read straight across it implies that intervention in a human would have to be prenatal too - which would make the therapy close to undeliverable. The gene-therapy study then found a postnatal-to-juvenile window in which AAV delivery still improved auditory brainstem response thresholds, preserved hair cells and partially restored the endocochlear potential, with the effect persisting into adulthood. Both results are in mice, and mouse and human cochlear maturation are not on the same schedule relative to birth: the human cochlea is functionally mature considerably earlier in relative terms than the mouse cochlea is. So neither result converts into a human date. The specific unknown is not whether restoring pendrin helps - that is established in the model - but whether any interval after human birth retains the plasticity the mouse experiments exploit. This is recorded as a HUMAN_MODEL_MISMATCH rather than a plain knowledge gap because the evidence is not absent. It exists, it is positive, and its translational validity to human disease is precisely what is unresolved.
Show evidence (4 references)
PMID:21965328 SUPPORT Model Organism
"Varying the temporal expression of Slc26a4 revealed that E16.5 to P2 was the critical interval in which pendrin was required for acquisition of normal hearing."
The mouse critical interval, most of which is prenatal.
PMID:41701544 SUPPORT Model Organism
"While gene therapy holds great potential, its postnatal application has remained unexplored because of the lack of suitable animal models and the challenges of prenatal intervention."
The authors' own framing of why the postnatal question was open, which is the mismatch this discussion records.
PMID:31784581 SUPPORT Model Organism
"it rescued hearing and vestibular function of mice in vivo"
The prenatal arm of the same question. Delivering the gene before the critical interval works; that it works there is what made the postnatal result surprising and what makes the human window the open question rather than a settled one.
+ 1 more reference
Why does it matter whether a SLC26A4 variant abolishes transport or abolishes trafficking?
INTERPRETATION pendred_variant_class_determines_therapy
Attached to
pathophysiology#Biallelic SLC26A4 Loss of Function treatments#Pendrin Corrector (Investigational)
Clinically the two look the same - no pendrin function, same hearing loss. Mechanistically they are different lesions, and the difference decides which of the emerging therapies could ever work for a given patient. A variant at the anion-binding site or in the transport gate produces a protein that reaches the apical membrane and cannot move anions. Nothing that improves its delivery helps. A variant such as p.His723Arg produces a protein that would work if it arrived, and is instead retained in the endoplasmic reticulum; restoring its surface expression restored its exchange activity in cells, which is the demonstration that the protein itself is competent. This is why the entry curates the two routes inside one pathophysiology node rather than collapsing them into "loss of function", and why the corrector's target_mechanisms link points at that node with an explicit statement that it has no target in a transport-dead variant. It also sets the scope of the corrector approach: p.His723Arg is the most common variant in East Asian populations, so a chaperone strategy is far more relevant to some populations than others.
Show evidence (1 reference)
PMID:37690388 SUPPORT In Vitro
"We observed that pendrin corrector (PC2-1) increased the surface expression and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic variant that causes Pendred syndrome and DFNB4."
Shows surface expression and function restored together, which is what identifies this variant as a trafficking rather than a transport lesion.
Why do relatives with the same SLC26A4 genotype have different inner-ear morphology?
KNOWLEDGE GAP pendred_intrafamilial_variability
Attached to
genetic#SLC26A4 phenotypes#Enlarged Vestibular Aqueduct
Within a single family carrying one SLC26A4 variant, inner-ear morphology can differ between affected members. Since genotype, and largely environment, are held constant, the variation has to come from somewhere else: unidentified modifier loci, or stochastic variation in a developmental process that has only a narrow window in which to go right. The second possibility is not a fallback explanation. This entry's central mechanistic claim is that the inner-ear lesion is developmental and window-bounded, and a process constrained to a short interval is exactly the kind that produces variable outcomes from identical inputs. If that is what is happening, then genotype will never predict inner-ear morphology well, and effort spent looking for modifiers would be better spent on the natural history. Distinguishing the two matters for counselling, since one implies a predictable familial pattern and the other does not.
Show evidence (1 reference)
PMID:38877731 SUPPORT Human Clinical
"We present a family of 4, all of whom possess sensorineural hearing loss due to the same homozygous SLC26A4 variant c.919-2A>G. Intriguingly, clinical manifestations, especially inner ear deformities, displayed variability among family members."
The observation itself - one homozygous variant, four affected relatives, differing inner-ear morphology - which is what makes the variability a genotype-held-constant finding rather than an impression.
⚙

Pathophysiology

9
Biallelic SLC26A4 Loss of Function
Loss of functional pendrin. Two distinct routes get there and they matter therapeutically rather than only descriptively: variants at the anion-binding site or the transport gate abolish exchange in a protein that reaches the membrane, whereas variants such as p.His723Arg fold badly and are retained in the endoplasmic reticulum, so the protein is competent but absent from the surface. Only the second class is addressable by a chaperone.
Genetic context SLC26A4 hgnc:8818 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns SLC26A4 (hgnc:8818). hgnc:8818 is a gene from the HUGO Gene Nomenclature Committee. functional_impact_category: LOSS_OF_FUNCTION
endoplasmic reticulum GO:0005783 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves endoplasmic reticulum (GO:0005783). GO:0005783 is a cellular component from the Gene Ontology.
Downstream
Loss of Apical Anion Exchange
Show evidence (3 references)
PMID:9398842 SUPPORT Human Clinical
"Using a positional cloning strategy, we have identified the gene (PDS) mutated in Pendred syndrome and found three apparently deleterious mutations, each segregating with the disease in the respective families in which they occur."
The gene identification, resting on cosegregation in three families.
PMID:37690388 SUPPORT In Vitro
"We observed that pendrin corrector (PC2-1) increased the surface expression and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic variant that causes Pendred syndrome and DFNB4."
Establishes the trafficking class by showing that restoring surface expression restores exchange activity - which is only possible if the protein itself is functional.
PMID:22116358 SUPPORT In Vitro
"As a general rule however, we observed a complete loss of function for all truncations and amino acid substitutions involving a proline."
The transport-dead half of the claim, which the first version of this entry asserted without evidence. Systematic functional testing of allelic variants, showing classes of variant that abolish activity outright.
Loss of Apical Anion Exchange
The transport step that both organ phenotypes share. Pendrin exchanges chloride for bicarbonate, iodide and other anions across the apical membrane; what the loss costs depends entirely on which epithelium is being asked to do what.
bicarbonate secretion into endolymph GO:0015701 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased bicarbonate secretion into endolymph, annotated with bicarbonate transport (GO:0015701). GO:0015701 is a biological process from the Gene Ontology. ↓ DECREASED
apical chloride/bicarbonate and chloride/iodide exchange GO:0140829 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves absent apical chloride/bicarbonate and chloride/iodide exchange, annotated with bicarbonate:monoatomic anion antiporter activity (GO:0140829). GO:0140829 is a molecular function from the Gene Ontology. ∅ ABSENT
apical plasma membrane GO:0016324 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves apical plasma membrane (GO:0016324). GO:0016324 is a cellular component from the Gene Ontology.
Downstream
Endolymphatic Acidification In the inner ear, where the anion moved is bicarbonate.
Endolymphatic Compartment Enlargement The structural consequence of disturbed endolymph handling, giving the enlarged vestibular aqueduct.
Impaired Thyroid Iodide Organification In the thyrocyte, where the anion moved is iodide.
Show evidence (1 reference)
PMID:22116353 SUPPORT Other
"Pendrin (SLC26A4), a Cl(-)/anion exchanger encoded by the gene PDS, is highly expressed in the kidney, thyroid and inner ear epithelia and is essential for bicarbonate secretion/chloride reabsorption, iodide accumulation and endolymph ion balance, respectively."
One sentence mapping the same transport function onto its three epithelia, which is the organising claim of this node.
Endolymphatic Acidification
Without bicarbonate secretion the endolymph becomes acidic. In the conditional mouse this is the measured proximate consequence of withdrawing pendrin, and it appears within the developmental window rather than accumulating over years.
endolymphatic sac UBERON:0002223 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in endolymphatic sac (UBERON:0002223). UBERON:0002223 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Doxycycline-inducible Slc26a4 transgenic mouse on the Slc26a4-null background Mouse recapitulates Withdrawing pendrin acidifies endolymph and collapses the endocochlear potential, establishing the sequence rather than inferring it from a constitutive null.
Downstream
Loss of Endocochlear Potential
Show evidence (1 reference)
PMID:21965328 SUPPORT Model Organism
"Lack of pendrin during this period led to endolymphatic acidification, loss of the endocochlear potential, and failure to acquire normal hearing."
The measured causal chain in the conditional mouse, quoted in full because it establishes three consecutive nodes at once.
Loss of Endocochlear Potential
The endocochlear potential is the battery that drives transduction current through the hair cells. It collapses when endolymph composition fails, and without it the hair cells cannot do their job however intact they are.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
cochlea UBERON:0001844 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cochlea (UBERON:0001844). UBERON:0001844 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Failure to Acquire Normal Hearing
Endolymphatic Compartment Enlargement
Dilation of the endolymphatic duct and sac, seen radiologically as the enlarged vestibular aqueduct that gives the phenotype its imaging name. It is a fixed structural malformation rather than a progressive lesion, which is why the imaging is stable while the hearing is not.
vestibular aqueduct UBERON:0002279 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vestibular aqueduct (UBERON:0002279). UBERON:0002279 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Failure to Acquire Normal Hearing The enlargement accompanies the hearing loss and marks the same underlying failure, but the step from a dilated compartment to a specific hearing deficit is not resolved separately from the endolymph-composition route.
Enlarged Vestibular Aqueduct
Incomplete Partition of the Cochlea Type II The cochlear partition anomaly accompanies the aqueduct enlargement in the same malformation spectrum; whether it arises from the same endolymph disturbance or from an independent developmental effect of pendrin loss is not resolved.
Show evidence (1 reference)
PMID:41701544 SUPPORT Model Organism
"the therapy preserved hair cells, reduced endolymphatic sac enlargement, partially restored the endocochlear potential, and mitigated inner ear structural degeneration"
Shows the enlargement responding to restoration of the gene, which ties it to pendrin loss rather than to a downstream consequence of deafness.
Impaired Thyroid Iodide Organification
Iodide reaches the follicular lumen less efficiently, so organification onto thyroglobulin is partial. The defect is partial rather than complete, and the entry does not claim pendrin is the only apical route - other channels can carry iodide, which is why the thyroid phenotype is variable where the inner-ear phenotype is not.
thyroid follicular cell CL:0002258 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves thyroid follicular cell (CL:0002258). CL:0002258 is a cell type from the Cell Ontology.
thyroid gland UBERON:0002046 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in thyroid gland (UBERON:0002046). UBERON:0002046 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Compensatory Thyroid Stimulation and Goitre Reduced hormone output raises TSH, which drives follicular hyperplasia.
Reduced Local Thyroid Hormone During Inner Ear Development
Iodide Organification Defect
Hypothyroidism Only where compensation fails; most patients remain euthyroid at the cost of a larger gland.
Show evidence (2 references)
PMID:28648509 SUPPORT Other
"Functional studies have demonstrated that pendrin can mediate iodide efflux in heterologous cells. This, together with the thyroid phenotype observed in humans (goiter, impaired iodine organification) suggests that pendrin could be involved in iodide efflux into the lumen, one of the steps..."
States the mechanism and, in the review's own hedged wording, its limits - which is why this node is worded as a partial defect rather than an absolute block.
PMID:28648509 SUPPORT Other
"Iodide efflux can, however, also occur in the absence of pendrin suggesting that other exchangers or channels are involved."
PARTIAL because it qualifies rather than supports the claim - the reason this entry does not present pendrin as the sole apical iodide route.
Reduced Local Thyroid Hormone During Inner Ear Development
A second, parallel route from the same protein to the same deafness. Thyroid hormone is required for cochlear maturation, and a mouse allele with a normal-sized thyroid and normal circulating hormone nevertheless showed atrophic follicles and inner-ear defects that resemble hypothyroidism - a thickened tectorial membrane, absent BK channel expression in inner hair cells, reduced inner-ear bone calcification. PROVISIONAL because it rests on one mouse allele and is proposed rather than established for human disease, and because it is a contributing route rather than a substitute for the endolymph mechanism.
Animal models
Slc26a4 loop/loop mouse Mouse partially recapitulates Shows atrophic thyroid follicles with normal circulating hormone alongside inner-ear defects characteristic of hypothyroidism - the observation the cochlear-hypothyroidism reading rests on.
Downstream
Failure to Acquire Normal Hearing Through the cochlear maturation defects that thyroid hormone deficiency produces.
Show evidence (2 references)
PMID:24760582 SUPPORT Model Organism
"The pathological inner ear hallmarks included thicker tectorial membrane with reduced β-tectorin protein expression, the absence of BK channel expression of inner hair cells, and reduced inner ear bone calcification."
The measured inner-ear phenotype that motivates the cochlear-hypothyroidism reading.
PMID:24760582 SUPPORT Model Organism
"We propose that insufficient availability of thyroid hormone during inner ear development plays an important role in the mechanism underlying deafness as a result of SLC26A4 mutations."
PARTIAL because the authors state this as a proposal from a mouse allele, which is why the node is graded PROVISIONAL.
Compensatory Thyroid Stimulation and Goitre
Rising TSH drives glandular enlargement, typically appearing in the second decade and typically with preserved or only mildly reduced thyroid function. Penetrance depends on iodine intake, so the same genotype gives goitre more often in a population without salt iodisation.
Downstream
Goitre
Failure to Acquire Normal Hearing
The clinical endpoint of both inner-ear routes. Two features distinguish it from most congenital hearing loss and both follow from the mechanism: some newborns pass screening, because the deficit is not always complete at birth; and the loss is characteristically fluctuating and step-wise rather than smoothly progressive.
Downstream
Sensorineural Hearing Loss
Vertigo Vestibular dysfunction accompanies the cochlear failure and shares the endolymph disturbance, but is not caused by the hearing loss itself.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pendred Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Ear 1
Vertigo FREQUENT HP:0002321 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vertigo (HP:0002321), qualified as temporality recurrent. HP:0002321 is a phenotype from the Human Phenotype Ontology.
Temporal: RECURRENT
Show evidence (2 references)
PMID:41066100 SUPPORT Human Clinical
"Recurrent vertigo (256 of 597 [42.9%]) and goiter (38 of 597 [6.4%]) were common comorbidities."
The measured vertigo frequency in a large EVA cohort.
PMID:20301640 SUPPORT Other
"Manifestations of vestibular dysfunction (such as head-tilting, vomiting, and/or delayed ambulation or clumsiness in a child who previously walked well) can precede or accompany the fluctuations in hearing typical of this disorder."
Describes how the vestibular phenotype actually presents in children, which is why it is missed.
Endocrine 2
Goitre FREQUENT Goiter HP:0000853 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Goiter (HP:0000853), qualified as course progressive. HP:0000853 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:20301640 SUPPORT Other
"Thyroid enlargement (goiter) occurs gradually and is typically evident in the second decade, especially if iodine is not routinely included in the diet."
States the timing and the iodine dependence together.
PMID:41066100 SUPPORT Human Clinical
"Recurrent vertigo (256 of 597 [42.9%]) and goiter (38 of 597 [6.4%]) were common comorbidities."
PARTIAL because the 6.4% is the goitre frequency in an EVA cohort in a salt-iodised population and in a young cohort, so it understates goitre in Pendred syndrome specifically rather than measuring it.
Hypothyroidism OCCASIONAL HP:0000821 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28648509 SUPPORT Other
"Pendred syndrome is an autosomal recessive disorder that is classically defined by the combination of sensorineural deafness/hearing impairment, goiter, and an abnormal organification of iodide with or without hypothyroidism."
The classical definition, which is explicit that hypothyroidism is optional within it.
Other 4
Sensorineural Hearing Loss OBLIGATE Bilateral sensorineural hearing impairment HP:0008619 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bilateral sensorineural hearing impairment (HP:0008619), qualified as course progressive. HP:0008619 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:20301640 SUPPORT Other
"The time of onset and type of presentation of the SNHL vary (such that some newborns pass their newborn hearing screening); however, by age three years most children have bilateral and severe-to-profound hearing loss."
States both the variability at birth and the severity reached in early childhood.
PMID:41066100 SUPPORT Human Clinical
"This study identified that 124 of 341 patients (36.36%) with EVA received passing newborn hearing screening results"
Quantifies the screening-escape fraction in a 2774-patient cohort, which is the number behind the delayed-diagnosis point.
Enlarged Vestibular Aqueduct VERY_FREQUENT HP:0011387 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Enlarged vestibular aqueduct (HP:0011387). HP:0011387 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34345941 SUPPORT Other
"The mutant SLC26A4 phenotype is characterized by inner ear malformations, including an enlarged vestibular aqueduct (EVA), incomplete cochlear partition type II and modiolar hypoplasia, progressive and fluctuating hearing loss, and vestibular dysfunction."
Places EVA among the inner-ear malformations of the SLC26A4 phenotype and names the accompanying cochlear findings.
PMID:30634102 SUPPORT Human Clinical
"No significant differences across bilateral status were observed in audiological measurements."
The measured result behind the claim that laterality does not predict severity.
Incomplete Partition of the Cochlea Type II FREQUENT HP:0000376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Incomplete partition of the cochlea type II (HP:0000376). HP:0000376 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34345941 SUPPORT Other
"The mutant SLC26A4 phenotype is characterized by inner ear malformations, including an enlarged vestibular aqueduct (EVA), incomplete cochlear partition type II and modiolar hypoplasia, progressive and fluctuating hearing loss, and vestibular dysfunction."
Names the cochlear partition anomaly as part of the SLC26A4 malformation spectrum, alongside EVA rather than instead of it.
Iodide Organification Defect OBLIGATE Thyroid defect in oxidation and organification of iodide HP:0008263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thyroid defect in oxidation and organification of iodide (HP:0008263). HP:0008263 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:11919333 SUPPORT Human Clinical
"Clinically, all patients had goiter with positive perchlorate test, hypothyroidism, and severe or profound sensorineural hearing loss."
The organification defect measured by perchlorate test in genetically confirmed patients, alongside the other two cardinal features.
PMID:34345941 SUPPORT Other
"A thyroid iodine organification defect can lead to multinodular goiter and distinguishes Pendred syndrome from DFNB4."
States that this phenotype is the discriminator between the two subtypes, which is what makes it load-bearing for this entry's scope decision.
PMID:21274344 SUPPORT Human Clinical
"Here we report four siblings who have goiter, severe hypothyroidism, a positive perchlorate discharge test and sensorineural deafness, but not the inner ear abnormality which is diagnostic for PDS."
PARTIAL, and deliberately so - these siblings have the organification defect and the deafness without the inner-ear malformation, which is the differential the perchlorate test alone cannot settle. Cited to bound the phenotype's specificity, not to support it.
🧬

Genetic Associations

1
SLC26A4
Gene: SLC26A4 hgnc:8818 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SLC26A4 (hgnc:8818). hgnc:8818 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (5 references)
PMID:34345941 SUPPORT Other
"In most European-Caucasian M1 patients, there is a haplotype that consists of 12 variants upstream of SLC26A4, called CEVA (Caucasian EVA), which acts as a pathogenic recessive allele in trans to mutations affecting the coding regions or splice sites of SLC26A4."
Defines CEVA and its mode of action, which is the reason a single coding allele can still be a recessive disease.
PMID:34345941 SUPPORT Other
"The phenotype in EVA patients with no mutant alleles of SLC26A4 (M0) has a very low recurrence probability and is likely to be caused by other factors."
The basis for treating M0 as probably a different disease rather than as undetected SLC26A4.
PMID:41066100 SUPPORT Human Clinical
"Genetic analysis revealed that 2661 of 2774 patients (95.9%) carried biallelic SLC26A4 variants"
The Chinese-cohort figure, quoted so the contrast with European cohorts is on the record rather than asserted.
+ 2 more references
Variants (2)
p.His723Arg Pathogenic
The trafficking-class allele, and the most prevalent variant causing Pendred syndrome and DFNB4 in East Asian populations. The protein folds badly and is retained in the endoplasmic reticulum rather than reaching the apical membrane, so the transport machinery itself is competent - which is why restoring its surface expression restores anion exchange, and why this is the one allele class a small-molecule chaperone can address. In an Okinawan cohort it accounted, with IVS15+5G>A, for about two thirds of alleles. Which emerging therapy is relevant to a patient is therefore partly a question of ancestry.
Also known as: H723R
Show evidence (2 references)
PMID:37690388 SUPPORT In Vitro
"We observed that pendrin corrector (PC2-1) increased the surface expression and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic variant that causes Pendred syndrome and DFNB4."
Establishes both the trafficking mechanism and this allele's prevalence, in the study that makes it the corrector's target.
PMID:23705809 SUPPORT Human Clinical
"We found a compound heterozygous mutation for IVS15 + 5G > A/H723R in nine patients (41%), a homozygous substitution of IVS15 + 5G > A in six patients (27%), and homozygous mutation for H723R in five patients (23%)."
The per-genotype breakdown in the founder population, showing this allele in both homozygous and compound-heterozygous configurations.
IVS15+5G>A Pathogenic
A splice-site variant that abolishes expression rather than producing a defective protein. It is the counterpart class to p.His723Arg and the reason the two are curated separately: there is nothing for a chaperone to rescue here, so a gene-replacement approach is the only one with a target.
Show evidence (1 reference)
PMID:23705809 SUPPORT Human Clinical
"The substitution of IVS15 + 5G > A leads to a loss of SLC26A expression and results in a phenotype of PS and EVA."
The mechanism - loss of expression, not a misfolded product - which is what places this allele in a different therapeutic class from H723R.
💊

Medical Actions

8
Audiological and Thyroid Surveillance
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Not treatment but the schedule that makes the rest of management possible. Audiometry every three to six months until age three and annually thereafter, with thyroid ultrasound from age ten. The audiometric interval is the mechanism-relevant part: this is a fluctuating, step-wise loss, so a hearing level measured once is not a trajectory, and habilitation has to be re-fitted against a moving target.
Show evidence (1 reference)
PMID:20301640 SUPPORT Other
"Audiometric testing every three to six months until age three years and annually thereafter; baseline ultrasound to assess thyroid size at age ten years, followed by repeat ultrasound every five to ten years based on findings on palpation of thyroid size."
The GeneReviews surveillance schedule, covering both organs this disease affects.
Hearing Habilitation
Action: hearing habilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hearing habilitation, annotated with Rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
Amplification and multidisciplinary hearing habilitation, which is the mainstay and is habilitation rather than treatment of the disease. Early auditory intervention is what protects speech and language development, and the fluctuating course means the fitting has to be revisited rather than set once.
Mechanism Target:
BYPASSES Failure to Acquire Normal Hearing — Amplifies the residual signal. It does nothing to the anion-transport lesion.
Show evidence (1 reference)
PMID:20301640 SUPPORT Other
"Habilitation options tailored to the degree and frequency of hearing loss can include hearing aids when hearing loss is mild to severe and consideration of cochlear implantation (CI) when hearing aids have had limited benefit."
The management algorithm as GeneReviews sets it out, including the threshold at which implantation is considered.
Cochlear Implantation
Action: cochlear implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear implantation, annotated with Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Considered where hearing aids have had limited benefit. It carries a specific and predictable perioperative issue in this disorder - a perilymph gusher - which is a consequence of the inner-ear malformation itself rather than of surgical technique, and is the reason the surgeon needs the diagnosis beforehand rather than afterwards.
Mechanism Target:
BYPASSES Failure to Acquire Normal Hearing — Substitutes for the transduction the cochlea can no longer perform, stimulating the auditory nerve directly.
Show evidence (1 reference)
PMID:20301640 SUPPORT Other
"it is essential that the treating otolaryngologist be aware of the possible perioperative complications (most commonly perilymph gusher/oozing) and postoperative complications (most commonly transient vertigo) in individuals with SLC26A4-SNHL"
The disease-specific surgical risk, which is the claim that makes this a separate treatment item rather than a line in the habilitation entry.
Levothyroxine for Thyroid Insufficiency
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: levothyroxine NCIT:C62080 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses levothyroxine (NCIT:C62080). NCIT:C62080 is a therapeutic agent from the NCI Thesaurus.
Replacement where thyroid function is inadequate or to suppress goitre growth. It addresses the thyroid arm only; there is no evidence here that it alters the hearing, and the developmental window for the inner ear has closed long before the goitre appears.
Mechanism Target:
MODULATES Compensatory Thyroid Stimulation and Goitre — Reduces the TSH drive that produces the enlargement.
Show evidence (1 reference)
PMID:20301640 SUPPORT Other
"Medical treatment of thyroid enlargement and/or abnormal thyroid function requires consultation with"
PARTIAL because GeneReviews directs the reader to specialist consultation rather than specifying an agent - so this item supports that the thyroid arm is treated, not that levothyroxine is the specified treatment.
Pendrin Corrector (Investigational)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
A small-molecule chaperone that restores surface expression of misfolded pendrin. In cells, PC2-1 restored both surface expression and anion-exchange activity of p.His723Arg, the most common variant in East Asian patients, and reached micromolar concentrations in cochlear perilymph in vivo. Preclinical only, and by construction it can only help the trafficking class of variants.
Mechanism Target:
RESTORES Biallelic SLC26A4 Loss of Function — Restores the protein to the membrane where the defect is folding rather than transport. It has no target in an anion-binding-site variant.
Show evidence (1 reference)
PMID:37690388 SUPPORT In Vitro
"These preclinical data support the hypothesis of the druggability of mutant pendrin using the novel corrector molecule PC2-1."
PARTIAL because the authors present this as preclinical support for druggability, not as demonstrated benefit.
Prenatal SLC26A4 Gene Transfer (Investigational)
Action: gene therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gene therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. Ontology label: Gene Therapy NCIT:C15238
Electroporation of SLC26A4 cDNA into the otocyst of Slc26a4-knockout mice before birth. It prevented endolymphatic enlargement and rescued both hearing and vestibular function - the strongest demonstration that the inner-ear lesion is preventable if the protein arrives early enough, and the reason the therapeutic window is the question the entry's central discussion turns on. Prenatal otocyst electroporation is not a route available in human patients.
Mechanism Target:
RESTORES Biallelic SLC26A4 Loss of Function — Supplies the gene before the critical interval rather than after it.
Show evidence (1 reference)
PMID:31784581 SUPPORT Model Organism
"supplementation of the target gene cDNA into the otocysts of homozygous Slc24a4 knockout mice significantly prevented enlargement of the endolymphatic space in the inner ear areas; moreover, it rescued hearing and vestibular function of mice in vivo"
Both the structural and the functional rescue. Note the source's own typo, "Slc24a4" for Slc26a4, reproduced as published.
CRISPR Exon Skipping (Investigational)
Action: gene therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gene therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. Ontology label: Gene Therapy NCIT:C15238
Editing to skip a premature termination codon arising from the c.919-2A>G splice variant. Recorded here because its result is informative and negative: the edit restored the protein and normal vestibular function, and hearing did not improve, with hair cell loss and elevated thresholds on pathology. That is a direct counterexample to the assumption that restoring pendrin restores hearing whenever it is done, and it concerns the same variant as the family in this entry's intrafamilial-variability discussion.
Mechanism Target:
RESTORES Biallelic SLC26A4 Loss of Function — Restores expression from the mutant allele. The restoration was achieved and did not deliver the hearing outcome, which is the finding worth carrying.
Show evidence (1 reference)
PMID:39232211 SUPPORT Model Organism
"However, despite these molecular achievements, hearing function did not show the expected improvement, consistent with observed pathology, including cochlear hair cell loss and elevated hearing thresholds."
PARTIAL because the molecular objective was met and the functional one was not. Carried as a negative result rather than omitted, since it constrains what restoring pendrin can be expected to achieve and when.
AAV SLC26A4 Gene Replacement (Investigational)
Action: gene therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gene therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. Ontology label: Gene Therapy NCIT:C15238
Delivery of SLC26A4 to the endolymphatic sac and cochlear lateral wall. The result that matters is that it worked postnatally in a mouse whose auditory phenotype resembles the human one, with effects persisting into adulthood - because the mouse critical-window data had made prenatal delivery look necessary. Whether a comparable postnatal window exists in humans is the central open question and is recorded as a knowledge gap.
Mechanism Target:
RESTORES Biallelic SLC26A4 Loss of Function — Supplies a functional copy of the gene, acting upstream of every node in this entry.
Show evidence (1 reference)
PMID:41701544 SUPPORT Model Organism
"Comprehensive phenotypic analyses revealed a critical therapeutic window spanning the neonatal and juvenile stages, within which AAV.Anc80L65-mediated SLC26A4 delivery significantly improved hearing, as evidenced by lower auditory brainstem response thresholds."
The postnatal window and the hearing benefit, measured by ABR threshold.
🌍

Environmental Factors

1
Dietary iodine intake
exposure to iodine ECTO:9000084 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to iodine (ECTO:9000084). ECTO:9000084 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Iodine status modifies the thyroid phenotype without touching the inner-ear one. Adequate dietary iodine lets a partially defective organification step keep up, so goitre is less frequent and less severe where salt is iodised; where it is not, the same genotypes present with the goitre that named the syndrome. This is why goitre frequency in a cohort describes a food policy as much as a gene, and why the syndromic/nonsyndromic label can differ between populations carrying identical variants.
Show evidence (2 references)
PMID:28648509 SUPPORT Other
"The thyroid phenotype is variable and may be modified by the nutritional iodine intake."
The exposure claim at entry level - that nutritional iodine is a modifier of the thyroid phenotype in this disease, which is what makes it worth recording as an exposure at all.
PMID:20301640 SUPPORT Other
"Thyroid enlargement (goiter) occurs gradually and is typically evident in the second decade, especially if iodine is not routinely included in the diet."
The dietary condition stated in the GeneReviews clinical description, independent of the mechanism link below.
Mechanism Target:
MODULATES Compensatory Thyroid Stimulation and Goitre — Sufficient iodide supply raises the substrate available to a partially impaired organification step, reducing the TSH drive that produces glandular enlargement. Recorded as MODULATES rather than PROTECTS_AGAINST because the sources state that the thyroid phenotype is modified by iodine intake, not that iodine prevents the goitre.
Show evidence (2 references)
PMID:28648509 SUPPORT Other
"The thyroid phenotype is variable and may be modified by the nutritional iodine intake."
States the modification directly, and in the hedged form the link's predicate is chosen to match.
PMID:20301640 SUPPORT Other
"Thyroid enlargement (goiter) occurs gradually and is typically evident in the second decade, especially if iodine is not routinely included in the diet."
The dietary condition under which the goitre is expected, from the GeneReviews clinical description.
🔬

Diagnosis

3
Temporal Bone Imaging
CT or MRI demonstrating the enlarged vestibular aqueduct, and with it the incomplete cochlear partition and modiolar hypoplasia that often accompany it. In practice the combination of audiology and imaging is what makes the diagnosis before genetics is available.
temporal bone CT or MRI NCIT:C16502 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:41066100 SUPPORT Human Clinical
"while 375 of 597 (62.8%) received a diagnosis through combined audiological and radiological assessments"
Quantifies how the diagnosis is actually reached in a large cohort.
SLC26A4 Molecular Testing
Establishes the diagnosis. A negative coding-region result in a patient with the imaging phenotype should raise the CEVA haplotype and structural or deep-intronic alleles rather than exclude the gene.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:20301640 SUPPORT Other
"The diagnosis of SLC26A4-SNHL is established in a proband with suggestive findings and biallelic pathogenic variants in SLC26A4 identified by molecular genetic testing."
The diagnostic criterion as GeneReviews states it.
Perchlorate Discharge Test
Measures whether iodide taken up by the thyroid has been organified: perchlorate displaces un-organified iodide, so a discharge above threshold reports a defect. It is what makes the syndromic/nonsyndromic distinction demonstrable rather than assumed. Two limits are worth stating. The defect is partial, so the test can be negative in a genetically confirmed patient - which is part of why iodine-replete populations report lower goitre and organification frequencies. And it is not specific: siblings with goitre, hypothyroidism, deafness and a positive discharge test but no inner-ear malformation have been reported as a pseudo-Pendred phenotype, so a positive test does not by itself make the diagnosis.
laboratory procedure NCIT:C25294 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:11919333 SUPPORT Human Clinical
"Clinically, all patients had goiter with positive perchlorate test, hypothyroidism, and severe or profound sensorineural hearing loss."
The test used in a genetically characterised series, positive across it.
PMID:21274344 SUPPORT Human Clinical
"Here we report four siblings who have goiter, severe hypothyroidism, a positive perchlorate discharge test and sensorineural deafness, but not the inner ear abnormality which is diagnostic for PDS."
PARTIAL because it bounds the test rather than supporting it - a positive discharge test with the full clinical triad and no inner-ear malformation, which is the specificity limit this diagnosis entry records.
📊

Prevalence

1
Non-African populations
Point Prevalence 7.5 per 100,000 (7.5–10.0) 1–9 per 100,000
Reported as 7.5-10 per 100,000 in non-African populations. The population qualifier is the source's own and is worth keeping: this entry's genetic section records that the proportion of EVA attributable to biallelic SLC26A4 differs markedly between cohorts, so a prevalence figure carries a population with it rather than describing the disease in general.
Show evidence (1 reference)
PMID:40956475 SUPPORT Human Clinical
"The prevalence of PDS in non-African populations is estimated to be between 7.5 and 10 per 100,000"
The published estimate with its population restriction stated in the same clause.
🐁

Animal Models

2
Doxycycline-inducible Slc26a4 transgenic mouse on the Slc26a4-null background
The model that turned pendrin's requirement into a time interval. All functional pendrin comes from the transgene, so expression can be started and stopped, and the hearing outcome read against when it was present.
Species
Mouse
Genotype
Slc26a4-null carrying a doxycycline-inducible Slc26a4 transgene
Publication
PMID:21965328
Pathograph links
Endolymphatic Acidification recapitulates fidelity: high Withdrawing pendrin acidifies endolymph and collapses the endocochlear potential, establishing the sequence rather than inferring it from a constitutive null.
Limitations: The developmental timing is mouse timing. Mapping E16.5-P2 onto a human gestational interval is exactly the step this model cannot make, and it is why the therapeutic window in humans is an open question rather than a converted date. The constitutive Slc26a4-null mouse, by contrast, is profoundly deaf with malformations more severe than the human phenotype, so severity in either mouse should not be read across to patients.
Readouts
Endocochlear potential
Direction: DECREASED
Interpretation: The electrophysiological consequence of failed endolymph handling, and the step that links the ionic lesion to the sensory one.
Show evidence (1 reference)
PMID:21965328 SUPPORT Model Organism
"Lack of pendrin during this period led to endolymphatic acidification, loss of the endocochlear potential, and failure to acquire normal hearing."
The measured chain including the endocochlear potential.
Show evidence (2 references)
PMID:21965328 SUPPORT Model Organism
"Varying the temporal expression of Slc26a4 revealed that E16.5 to P2 was the critical interval in which pendrin was required for acquisition of normal hearing."
The result that makes this model informative - a defined interval rather than a presence/absence phenotype.
PMID:21965328 SUPPORT Model Organism
"Doxycycline initiation at E18.5 or discontinuation at E17.5 resulted in partial hearing loss approximating the human EVA auditory phenotype."
Establishes that partial timing gives the partial human phenotype, which is what makes this model closer to patients than the constitutive null.
Slc26a4 loop/loop mouse
A mouse that is profoundly deaf with a normal-sized thyroid gland, modelling the nonsyndromic end of the spectrum, and in which the thyroid nevertheless turns out to be histologically abnormal.
Species
Mouse
Genotype
Slc26a4 loop/loop
Publication
PMID:24760582
Pathograph links
Reduced Local Thyroid Hormone During Inner Ear Development partially recapitulates fidelity: moderate Shows atrophic thyroid follicles with normal circulating hormone alongside inner-ear defects characteristic of hypothyroidism - the observation the cochlear-hypothyroidism reading rests on.
Limitations: Circulating thyroid hormone was within the normal range, so the model demonstrates a histological thyroid abnormality and an inner-ear phenotype resembling hypothyroidism, not a measured local hormone deficit in the cochlea. The causal step from one to the other is the authors' proposal. The mouse also lacks goitre entirely, so it does not model the syndromic thyroid phenotype at all.
Readouts
Inner hair cell BK channel expression
Direction: ABOLISHED
Interpretation: A maturation marker known to be thyroid-hormone-dependent, absent here - which is the specific reason the phenotype is read as cochlear hypothyroidism rather than as generic inner-ear damage.
Show evidence (1 reference)
PMID:24760582 SUPPORT Model Organism
"the absence of BK channel expression of inner hair cells"
The measured absence behind this readout.
Show evidence (1 reference)
PMID:24760582 SUPPORT Model Organism
"Histological analysis of the thyroid gland revealed defective morphology, with a majority of atrophic microfollicles, while measurable thyroid hormone in blood serum was within the normal range."
Establishes both what the model shows and the limit of what it shows - abnormal histology with normal circulating hormone.
{ }

Source YAML

click to show 
name: Pendred Syndrome
creation_date: "2026-08-28T16:30:00Z"
category: Mendelian
description: >-
  Pendred syndrome is one protein failing in two epithelia, and almost everything
  clinically distinctive about it follows from that. Pendrin, encoded by
  SLC26A4, is an apical anion exchanger that moves chloride, bicarbonate and
  iodide. In the inner ear it secretes bicarbonate into endolymph; in the thyroid
  it sits at the apical membrane of the follicular cell facing the lumen, where
  iodide has to cross to be organified. Losing it therefore gives sensorineural
  hearing loss with an enlarged vestibular aqueduct and, separately, a partial
  iodide organification defect with goitre.

  The inner-ear arm is developmental and time-limited, which is the fact that
  organises the rest of the entry. Conditional restoration of Slc26a4 in mice
  showed that pendrin is required across a narrow perinatal interval, and that
  its absence in that interval acidifies endolymph, collapses the endocochlear
  potential and leaves the animal unable to acquire normal hearing. So the injury
  is not a slow degeneration that could be arrested at any point - it is a
  developmental failure with a closing window, and that is what any
  disease-modifying therapy has to reach.

  The second thing worth stating plainly is that this is the syndromic end of a
  spectrum, not a separate disease from DFNB4. The same biallelic SLC26A4
  genotypes produce hearing loss with an organification defect in some people and
  without one in others, and iodine intake modifies which. The thyroid phenotype
  is what names the syndrome; it is not what causes the deafness.
disease_term:
  preferred_term: Pendred syndrome
  term:
    id: MONDO:0010134
    label: Pendred syndrome
synonyms:
- PDS
- goiter-deafness syndrome
- deafness with goitre
- autosomal recessive sensorineural hearing impairment and goiter
parents:
- Hearing loss disorder
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Biallelic SLC26A4 variants. The allelic accounting is unusually well
    characterised and is curated in the genetic section, because a substantial
    minority of patients with the same inner-ear phenotype carry only one
    detectable coding allele or none.
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of SLC26A4-SNHL is established in a proband with suggestive findings
      and biallelic pathogenic variants in SLC26A4 identified by molecular genetic testing.
    explanation: GeneReviews states the biallelic requirement as the diagnostic criterion.
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If both parents are known to be heterozygous for an SLC26A4 pathogenic variant,
      each sib of the proband has at conception a 25% chance of having SLC26A4-SNHL, a 50%
      chance of being heterozygous, and a 25% chance of inheriting neither of the pathogenic
      variants.
    explanation: The transmission risk, which is the fact a family actually needs from the
      inheritance mode. Note the conditional the sentence opens with - it holds once both
      parents are established as carriers, which the entry's own account of CEVA and
      deep-intronic alleles shows is not automatic.
has_subtypes:
- name: Pendred syndrome
  display_name: Pendred syndrome, with thyroid involvement
  description: >-
    The syndromic phenotype: SLC26A4 hearing loss plus a demonstrable iodide
    organification defect, usually with goitre. Recognised more often where salt
    is not iodised.
- name: DFNB4
  display_name: DFNB4, nonsyndromic SLC26A4 hearing loss with EVA
  description: >-
    The same inner-ear disease without demonstrable thyroid involvement, also
    called nonsyndromic enlargement of the vestibular aqueduct. Curated as a
    subtype rather than as a separate entry because the gene, the inner-ear
    mechanism and the allelic spectrum are the same; it is the organification
    defect that separates the two labels.
  evidence:
  - reference: PMID:34345941
    reference_title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing
      loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: A thyroid iodine organification defect can lead to multinodular goiter and
      distinguishes Pendred syndrome from DFNB4.
    explanation: States exactly what separates the two labels, and by implication what
      does not.
pathophysiology:
- name: Biallelic SLC26A4 Loss of Function
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Loss of functional pendrin. Two distinct routes get there and they matter
    therapeutically rather than only descriptively: variants at the anion-binding
    site or the transport gate abolish exchange in a protein that reaches the
    membrane, whereas variants such as p.His723Arg fold badly and are retained in
    the endoplasmic reticulum, so the protein is competent but absent from the
    surface. Only the second class is addressable by a chaperone.
  genetic_context:
    gene:
      preferred_term: SLC26A4
      term:
        id: hgnc:8818
        label: SLC26A4
    functional_impact_category: LOSS_OF_FUNCTION
  cellular_components:
  - preferred_term: endoplasmic reticulum
    term:
      id: GO:0005783
      label: endoplasmic reticulum
  downstream:
  - target: Loss of Apical Anion Exchange
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:9398842
    reference_title: Pendred syndrome is caused by mutations in a putative sulphate transporter
      gene (PDS).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Using a positional cloning strategy, we have identified the gene (PDS) mutated
      in Pendred syndrome and found three apparently deleterious mutations, each segregating
      with the disease in the respective families in which they occur.
    explanation: The gene identification, resting on cosegregation in three families.
  - reference: PMID:37690388
    reference_title: Novel small molecule-mediated restoration of the surface expression
      and anion exchange activity of mutated pendrin causing Pendred syndrome and DFNB4.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We observed that pendrin corrector (PC2-1) increased the surface expression
      and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic
      variant that causes Pendred syndrome and DFNB4.
    explanation: Establishes the trafficking class by showing that restoring surface
      expression restores exchange activity - which is only possible if the protein itself
      is functional.
  - reference: PMID:22116358
    reference_title: Molecular and functional characterization of human pendrin and its allelic
      variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: As a general rule however, we observed a complete loss of function for all truncations
      and amino acid substitutions involving a proline.
    explanation: The transport-dead half of the claim, which the first version of this entry
      asserted without evidence. Systematic functional testing of allelic variants, showing
      classes of variant that abolish activity outright.
- name: Loss of Apical Anion Exchange
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    The transport step that both organ phenotypes share. Pendrin exchanges
    chloride for bicarbonate, iodide and other anions across the apical membrane;
    what the loss costs depends entirely on which epithelium is being asked to do
    what.
  molecular_functions:
  - preferred_term: apical chloride/bicarbonate and chloride/iodide exchange
    modifier: ABSENT
    term:
      id: GO:0140829
      label: bicarbonate:monoatomic anion antiporter activity
  biological_processes:
  - preferred_term: bicarbonate secretion into endolymph
    modifier: DECREASED
    term:
      id: GO:0015701
      label: bicarbonate transport
  cellular_components:
  - preferred_term: apical plasma membrane
    term:
      id: GO:0016324
      label: apical plasma membrane
  chemical_entities:
  - preferred_term: bicarbonate
    term:
      id: CHEBI:17544
      label: hydrogencarbonate
  - preferred_term: iodide
    term:
      id: CHEBI:16382
      label: iodide
  downstream:
  - target: Endolymphatic Acidification
    causal_link_type: DIRECT
    description: >-
      In the inner ear, where the anion moved is bicarbonate.
  - target: Endolymphatic Compartment Enlargement
    causal_link_type: DIRECT
    description: >-
      The structural consequence of disturbed endolymph handling, giving the
      enlarged vestibular aqueduct.
  - target: Impaired Thyroid Iodide Organification
    causal_link_type: DIRECT
    description: >-
      In the thyrocyte, where the anion moved is iodide.
  evidence:
  - reference: PMID:22116353
    reference_title: Transcriptional regulation of the pendrin gene.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Pendrin (SLC26A4), a Cl(-)/anion exchanger encoded by the gene PDS, is highly
      expressed in the kidney, thyroid and inner ear epithelia and is essential for bicarbonate
      secretion/chloride reabsorption, iodide accumulation and endolymph ion balance, respectively.
    explanation: One sentence mapping the same transport function onto its three
      epithelia, which is the organising claim of this node.
- name: Endolymphatic Acidification
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  description: >-
    Without bicarbonate secretion the endolymph becomes acidic. In the
    conditional mouse this is the measured proximate consequence of withdrawing
    pendrin, and it appears within the developmental window rather than
    accumulating over years.
  locations:
  - preferred_term: endolymphatic sac
    term:
      id: UBERON:0002223
      label: endolymphatic sac
  downstream:
  - target: Loss of Endocochlear Potential
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21965328
    reference_title: Mouse model of enlarged vestibular aqueducts defines temporal requirement
      of Slc26a4 expression for hearing acquisition.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Lack of pendrin during this period led to endolymphatic acidification, loss
      of the endocochlear potential, and failure to acquire normal hearing.
    explanation: The measured causal chain in the conditional mouse, quoted in full because
      it establishes three consecutive nodes at once.
- name: Loss of Endocochlear Potential
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  description: >-
    The endocochlear potential is the battery that drives transduction current
    through the hair cells. It collapses when endolymph composition fails, and
    without it the hair cells cannot do their job however intact they are.
  locations:
  - preferred_term: cochlea
    term:
      id: UBERON:0001844
      label: cochlea
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  downstream:
  - target: Failure to Acquire Normal Hearing
    causal_link_type: DIRECT
- name: Endolymphatic Compartment Enlargement
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  description: >-
    Dilation of the endolymphatic duct and sac, seen radiologically as the
    enlarged vestibular aqueduct that gives the phenotype its imaging name. It is
    a fixed structural malformation rather than a progressive lesion, which is
    why the imaging is stable while the hearing is not.
  locations:
  - preferred_term: vestibular aqueduct
    term:
      id: UBERON:0002279
      label: vestibular aqueduct
  downstream:
  - target: Failure to Acquire Normal Hearing
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The enlargement accompanies the hearing loss and marks the same underlying
      failure, but the step from a dilated compartment to a specific hearing
      deficit is not resolved separately from the endolymph-composition route.
  - target: Enlarged Vestibular Aqueduct
    causal_link_type: DIRECT
  - target: Incomplete Partition of the Cochlea Type II
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The cochlear partition anomaly accompanies the aqueduct enlargement in the
      same malformation spectrum; whether it arises from the same endolymph
      disturbance or from an independent developmental effect of pendrin loss is
      not resolved.
  evidence:
  - reference: PMID:41701544
    reference_title: Postnatal Slc26a4 gene therapy improves hearing and structural integrity
      in a hereditary hearing loss model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the therapy preserved hair cells, reduced endolymphatic sac enlargement, partially
      restored the endocochlear potential, and mitigated inner ear structural degeneration
    explanation: Shows the enlargement responding to restoration of the gene, which ties
      it to pendrin loss rather than to a downstream consequence of deafness.
- name: Impaired Thyroid Iodide Organification
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Iodide reaches the follicular lumen less efficiently, so organification onto
    thyroglobulin is partial. The defect is partial rather than complete, and the
    entry does not claim pendrin is the only apical route - other channels can
    carry iodide, which is why the thyroid phenotype is variable where the
    inner-ear phenotype is not.
  cell_types:
  - preferred_term: thyroid follicular cell
    term:
      id: CL:0002258
      label: thyroid follicular cell
  locations:
  - preferred_term: thyroid gland
    term:
      id: UBERON:0002046
      label: thyroid gland
  downstream:
  - target: Compensatory Thyroid Stimulation and Goitre
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced hormone output raises TSH, which drives follicular hyperplasia.
  - target: Reduced Local Thyroid Hormone During Inner Ear Development
    causal_link_type: DIRECT
  - target: Iodide Organification Defect
    causal_link_type: DIRECT
  - target: Hypothyroidism
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Only where compensation fails; most patients remain euthyroid at the cost of
      a larger gland.
  evidence:
  - reference: PMID:28648509
    reference_title: Pendred syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Functional studies have demonstrated that pendrin can mediate iodide efflux
      in heterologous cells. This, together with the thyroid phenotype observed in humans
      (goiter, impaired iodine organification) suggests that pendrin could be involved in
      iodide efflux into the lumen, one of the steps required for thyroid hormone synthesis.
    explanation: States the mechanism and, in the review's own hedged wording, its limits -
      which is why this node is worded as a partial defect rather than an absolute block.
  - reference: PMID:28648509
    reference_title: Pendred syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Iodide efflux can, however, also occur in the absence of pendrin suggesting
      that other exchangers or channels are involved.
    explanation: PARTIAL because it qualifies rather than supports the claim - the reason
      this entry does not present pendrin as the sole apical iodide route.
- name: Reduced Local Thyroid Hormone During Inner Ear Development
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    A second, parallel route from the same protein to the same deafness. Thyroid
    hormone is required for cochlear maturation, and a mouse allele with a
    normal-sized thyroid and normal circulating hormone nevertheless showed
    atrophic follicles and inner-ear defects that resemble hypothyroidism - a
    thickened tectorial membrane, absent BK channel expression in inner hair
    cells, reduced inner-ear bone calcification. PROVISIONAL because it rests on
    one mouse allele and is proposed rather than established for human disease,
    and because it is a contributing route rather than a substitute for the
    endolymph mechanism.
  downstream:
  - target: Failure to Acquire Normal Hearing
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Through the cochlear maturation defects that thyroid hormone deficiency
      produces.
  evidence:
  - reference: PMID:24760582
    reference_title: Atrophic thyroid follicles and inner ear defects reminiscent of cochlear
      hypothyroidism in Slc26a4-related deafness.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The pathological inner ear hallmarks included thicker tectorial membrane with
      reduced β-tectorin protein expression, the absence of BK channel expression of inner
      hair cells, and reduced inner ear bone calcification.
    explanation: The measured inner-ear phenotype that motivates the cochlear-hypothyroidism
      reading.
  - reference: PMID:24760582
    reference_title: Atrophic thyroid follicles and inner ear defects reminiscent of cochlear
      hypothyroidism in Slc26a4-related deafness.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We propose that insufficient availability of thyroid hormone during inner ear
      development plays an important role in the mechanism underlying deafness as a result
      of SLC26A4 mutations.
    explanation: PARTIAL because the authors state this as a proposal from a mouse allele,
      which is why the node is graded PROVISIONAL.
- name: Compensatory Thyroid Stimulation and Goitre
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: >-
    Rising TSH drives glandular enlargement, typically appearing in the second
    decade and typically with preserved or only mildly reduced thyroid function.
    Penetrance depends on iodine intake, so the same genotype gives goitre more
    often in a population without salt iodisation.
  downstream:
  - target: Goitre
    causal_link_type: DIRECT
- name: Failure to Acquire Normal Hearing
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  description: >-
    The clinical endpoint of both inner-ear routes. Two features distinguish it
    from most congenital hearing loss and both follow from the mechanism: some
    newborns pass screening, because the deficit is not always complete at birth;
    and the loss is characteristically fluctuating and step-wise rather than
    smoothly progressive.
  downstream:
  - target: Sensorineural Hearing Loss
    causal_link_type: DIRECT
  - target: Vertigo
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Vestibular dysfunction accompanies the cochlear failure and shares the
      endolymph disturbance, but is not caused by the hearing loss itself.
phenotypes:
- category: Auditory
  name: Sensorineural Hearing Loss
  frequency: OBLIGATE
  description: >-
    Bilateral in most, and severe to profound in most children by age three. It
    is progressive and characteristically fluctuating - patients describe
    step-wise drops, sometimes after minor head trauma. A substantial minority
    pass newborn hearing screening, which is a practical reason the diagnosis is
    delayed.
  phenotype_term:
    preferred_term: Bilateral sensorineural hearing impairment
    term:
      id: HP:0008619
      label: Bilateral sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The time of onset and type of presentation of the SNHL vary (such that some
      newborns pass their newborn hearing screening); however, by age three years most children
      have bilateral and severe-to-profound hearing loss.
    explanation: States both the variability at birth and the severity reached in early
      childhood.
  - reference: PMID:41066100
    reference_title: Reevaluation of Enlarged Vestibular Aqueduct.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study identified that 124 of 341 patients (36.36%) with EVA received passing
      newborn hearing screening results
    explanation: Quantifies the screening-escape fraction in a 2774-patient cohort, which
      is the number behind the delayed-diagnosis point.
- category: Auditory
  name: Enlarged Vestibular Aqueduct
  frequency: VERY_FREQUENT
  description: >-
    The radiological hallmark, usually bilateral but sometimes unilateral.
    Laterality does not predict hearing severity, which is worth stating because
    the intuition runs the other way.
  phenotype_term:
    preferred_term: Enlarged vestibular aqueduct
    term:
      id: HP:0011387
      label: Enlarged vestibular aqueduct
  evidence:
  - reference: PMID:34345941
    reference_title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing
      loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The mutant SLC26A4 phenotype is characterized by inner ear malformations, including
      an enlarged vestibular aqueduct (EVA), incomplete cochlear partition type II and modiolar
      hypoplasia, progressive and fluctuating hearing loss, and vestibular dysfunction.
    explanation: Places EVA among the inner-ear malformations of the SLC26A4 phenotype and
      names the accompanying cochlear findings.
  - reference: PMID:30634102
    reference_title: Hearing loss in unilateral and bilateral enlarged vestibular aqueduct
      syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No significant differences across bilateral status were observed in audiological
      measurements.
    explanation: The measured result behind the claim that laterality does not predict
      severity.
- category: Auditory
  name: Incomplete Partition of the Cochlea Type II
  frequency: FREQUENT
  description: >-
    A cochlear malformation with a deficient interscalar septum, accompanying the
    enlarged vestibular aqueduct in the same imaging spectrum. Often reported
    together with modiolar hypoplasia.
  phenotype_term:
    preferred_term: Incomplete partition of the cochlea type II
    term:
      id: HP:0000376
      label: Incomplete partition of the cochlea type II
  evidence:
  - reference: PMID:34345941
    reference_title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing
      loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The mutant SLC26A4 phenotype is characterized by inner ear malformations, including
      an enlarged vestibular aqueduct (EVA), incomplete cochlear partition type II and modiolar
      hypoplasia, progressive and fluctuating hearing loss, and vestibular dysfunction.
    explanation: Names the cochlear partition anomaly as part of the SLC26A4 malformation
      spectrum, alongside EVA rather than instead of it.
- category: Endocrine
  name: Iodide Organification Defect
  frequency: OBLIGATE
  subtype: Pendred syndrome
  description: >-
    Partial failure to incorporate iodide onto thyroglobulin, demonstrated by a
    positive perchlorate discharge test. This is the discriminating feature of the
    syndrome: it is what separates Pendred syndrome from DFNB4 in patients whose
    inner-ear disease is identical, and it is the reason this entry curates the
    two as subtypes of one disease rather than as one disease with an incidental
    thyroid finding.

    Graded OBLIGATE because the subtype is defined by it: a patient without a
    demonstrable defect is DFNB4 by definition. That is a statement about the
    definition, not about test sensitivity - the defect is partial and a
    confirmed patient can discharge normally, which is why the diagnosis entry
    records the perchlorate test's limits separately.
  phenotype_term:
    preferred_term: Thyroid defect in oxidation and organification of iodide
    term:
      id: HP:0008263
      label: Thyroid defect in oxidation and organification of iodide
  evidence:
  - reference: PMID:11919333
    reference_title: 'Differential diagnosis between Pendred and pseudo-Pendred syndromes:
      clinical, radiologic, and molecular studies.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinically, all patients had goiter with positive perchlorate test, hypothyroidism,
      and severe or profound sensorineural hearing loss.
    explanation: The organification defect measured by perchlorate test in genetically
      confirmed patients, alongside the other two cardinal features.
  - reference: PMID:34345941
    reference_title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing
      loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: A thyroid iodine organification defect can lead to multinodular goiter and
      distinguishes Pendred syndrome from DFNB4.
    explanation: States that this phenotype is the discriminator between the two subtypes,
      which is what makes it load-bearing for this entry's scope decision.
  - reference: PMID:21274344
    reference_title: "Congenital goitrous hypothyroidism, deafness and iodide organification defect in four siblings: Pendred or pseudo-Pendred syndrome?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we report four siblings who have goiter, severe hypothyroidism, a positive
      perchlorate discharge test and sensorineural deafness, but not the inner ear abnormality
      which is diagnostic for PDS.
    explanation: PARTIAL, and deliberately so - these siblings have the organification defect
      and the deafness without the inner-ear malformation, which is the differential the
      perchlorate test alone cannot settle. Cited to bound the phenotype's specificity, not
      to support it.
- category: Endocrine
  name: Goitre
  frequency: FREQUENT
  subtype: Pendred syndrome
  description: >-
    Thyroid enlargement, appearing gradually and typically in the second decade.
    It is the feature that names the syndrome and the one whose frequency depends
    on the population's iodine intake - which is why a cohort frequency for it
    describes a health system as much as a genotype.
  phenotype_term:
    preferred_term: Goiter
    term:
      id: HP:0000853
      label: Goiter
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Thyroid enlargement (goiter) occurs gradually and is typically evident in the
      second decade, especially if iodine is not routinely included in the diet.
    explanation: States the timing and the iodine dependence together.
  - reference: PMID:41066100
    reference_title: Reevaluation of Enlarged Vestibular Aqueduct.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recurrent vertigo (256 of 597 [42.9%]) and goiter (38 of 597 [6.4%]) were common
      comorbidities.
    explanation: PARTIAL because the 6.4% is the goitre frequency in an EVA cohort in a
      salt-iodised population and in a young cohort, so it understates goitre in Pendred
      syndrome specifically rather than measuring it.
- category: Endocrine
  name: Hypothyroidism
  frequency: OCCASIONAL
  subtype: Pendred syndrome
  description: >-
    Most patients are euthyroid; a minority are hypothyroid. The organification
    defect is partial, so thyroid function is often maintained at the cost of a
    larger gland.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  evidence:
  - reference: PMID:28648509
    reference_title: Pendred syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Pendred syndrome is an autosomal recessive disorder that is classically defined
      by the combination of sensorineural deafness/hearing impairment, goiter, and an abnormal
      organification of iodide with or without hypothyroidism.
    explanation: The classical definition, which is explicit that hypothyroidism is
      optional within it.
- category: Vestibular
  name: Vertigo
  frequency: FREQUENT
  description: >-
    Vestibular dysfunction is common and under-studied relative to the hearing
    loss. In children it can present as head-tilting, vomiting or new clumsiness
    rather than as reported dizziness, and it may precede the hearing
    fluctuations.
  phenotype_term:
    preferred_term: Vertigo
    term:
      id: HP:0002321
      label: Vertigo
    temporality: RECURRENT
  evidence:
  - reference: PMID:41066100
    reference_title: Reevaluation of Enlarged Vestibular Aqueduct.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recurrent vertigo (256 of 597 [42.9%]) and goiter (38 of 597 [6.4%]) were common
      comorbidities.
    explanation: The measured vertigo frequency in a large EVA cohort.
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Manifestations of vestibular dysfunction (such as head-tilting, vomiting, and/or
      delayed ambulation or clumsiness in a child who previously walked well) can precede
      or accompany the fluctuations in hearing typical of this disorder.
    explanation: Describes how the vestibular phenotype actually presents in children,
      which is why it is missed.
prevalence:
- population: Non-African populations
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 7.5
  rate_low: 7.5
  rate_high: 10.0
  notes: >-
    Reported as 7.5-10 per 100,000 in non-African populations. The population
    qualifier is the source's own and is worth keeping: this entry's genetic
    section records that the proportion of EVA attributable to biallelic SLC26A4
    differs markedly between cohorts, so a prevalence figure carries a population
    with it rather than describing the disease in general.
  evidence:
  - reference: PMID:40956475
    reference_title: Prevalence of pendrin defects in sudanese families with congenital hypothyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The prevalence of PDS in non-African populations is estimated to be between
      7.5 and 10 per 100,000
    explanation: The published estimate with its population restriction stated in the same
      clause.
genetic:
- name: SLC26A4
  gene_term:
    preferred_term: SLC26A4
    term:
      id: hgnc:8818
      label: SLC26A4
  relationship_type: CAUSATIVE
  notes: >-
    The allelic accounting is the part of this gene worth curating carefully,
    because "biallelic SLC26A4" does not describe every patient with the
    phenotype. Patients are classified by how many mutant coding or splice-site
    alleles are detectable: M2 with two, M1 with one, M0 with none. In European
    populations most M1 patients carry CEVA, a haplotype of twelve variants
    upstream of the gene that behaves as a pathogenic recessive allele in trans,
    and M1-plus-CEVA gives a milder phenotype than M2. M0 patients have a very
    low recurrence probability and are probably a different disease.

    Two consequences for how this entry should be read. A negative coding-region
    result does not exclude SLC26A4, because the second hit may be regulatory.
    And cohort ascertainment matters: a Chinese cohort found biallelic variants
    in 95.9% of EVA patients, where roughly half of European EVA is not
    biallelic, so a single figure for "the proportion of EVA that is SLC26A4" is
    a statement about a population rather than about the gene.

    Founder alleles sharpen that further. In Okinawa, IVS15+5G>A and H723R
    together account for roughly two thirds of alleles, and the two act by
    different routes - one abolishes expression, the other misfolds a competent
    protein. Both are curated as structured variants below rather than described
    only here, because which emerging therapy is relevant to a patient turns on
    which class their alleles fall into.
  evidence:
  - reference: PMID:34345941
    reference_title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing
      loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In most European-Caucasian M1 patients, there is a haplotype that consists
      of 12 variants upstream of SLC26A4, called CEVA (Caucasian EVA), which acts as a pathogenic
      recessive allele in trans to mutations affecting the coding regions or splice sites
      of SLC26A4.
    explanation: Defines CEVA and its mode of action, which is the reason a single coding
      allele can still be a recessive disease.
  - reference: PMID:34345941
    reference_title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing
      loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The phenotype in EVA patients with no mutant alleles of SLC26A4 (M0) has a
      very low recurrence probability and is likely to be caused by other factors.
    explanation: The basis for treating M0 as probably a different disease rather than as
      undetected SLC26A4.
  - reference: PMID:41066100
    reference_title: Reevaluation of Enlarged Vestibular Aqueduct.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic analysis revealed that 2661 of 2774 patients (95.9%) carried biallelic
      SLC26A4 variants
    explanation: The Chinese-cohort figure, quoted so the contrast with European cohorts
      is on the record rather than asserted.
  - reference: PMID:41066100
    reference_title: Reevaluation of Enlarged Vestibular Aqueduct.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: with 70 (2.5%) attributable to copy number variants and 13 (0.5%) to a deep-intronic
      variant (c.304 + 941C>T) that affected splicing
    explanation: Quantifies the structural and deep-intronic alleles that a coding-region
      panel misses - the concrete reason a negative sequencing result should not close the
      question.
  - reference: PMID:23705809
    reference_title: Pathogenic substitution of IVS15 + 5G > A in SLC26A4 in patients of
      Okinawa Islands with enlarged vestibular aqueduct syndrome or Pendred syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most prevalent types of SLC26A4 alleles were IVS15 + 5G > A and H723R,
      which both accounted for 15/22 (68%) of the patients.
    explanation: Founder alleles in an Okinawan cohort, and the basis for the two structured
      variant records below.
  variants:
  - name: p.His723Arg
    description: >-
      The trafficking-class allele, and the most prevalent variant causing Pendred
      syndrome and DFNB4 in East Asian populations. The protein folds badly and is
      retained in the endoplasmic reticulum rather than reaching the apical
      membrane, so the transport machinery itself is competent - which is why
      restoring its surface expression restores anion exchange, and why this is
      the one allele class a small-molecule chaperone can address. In an Okinawan
      cohort it accounted, with IVS15+5G>A, for about two thirds of alleles. Which
      emerging therapy is relevant to a patient is therefore partly a question of
      ancestry.
    synonyms:
    - H723R
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:37690388
      reference_title: Novel small molecule-mediated restoration of the surface expression
        and anion exchange activity of mutated pendrin causing Pendred syndrome and DFNB4.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We observed that pendrin corrector (PC2-1) increased the surface expression
        and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic
        variant that causes Pendred syndrome and DFNB4.
      explanation: Establishes both the trafficking mechanism and this allele's prevalence,
        in the study that makes it the corrector's target.
    - reference: PMID:23705809
      reference_title: Pathogenic substitution of IVS15 + 5G > A in SLC26A4 in patients of
        Okinawa Islands with enlarged vestibular aqueduct syndrome or Pendred syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We found a compound heterozygous mutation for IVS15 + 5G > A/H723R in nine
        patients (41%), a homozygous substitution of IVS15 + 5G > A in six patients (27%),
        and homozygous mutation for H723R in five patients (23%).
      explanation: The per-genotype breakdown in the founder population, showing this allele
        in both homozygous and compound-heterozygous configurations.
  - name: IVS15+5G>A
    description: >-
      A splice-site variant that abolishes expression rather than producing a
      defective protein. It is the counterpart class to p.His723Arg and the reason
      the two are curated separately: there is nothing for a chaperone to rescue
      here, so a gene-replacement approach is the only one with a target.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:23705809
      reference_title: Pathogenic substitution of IVS15 + 5G > A in SLC26A4 in patients of
        Okinawa Islands with enlarged vestibular aqueduct syndrome or Pendred syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The substitution of IVS15 + 5G > A leads to a loss of SLC26A expression and
        results in a phenotype of PS and EVA.
      explanation: The mechanism - loss of expression, not a misfolded product - which is
        what places this allele in a different therapeutic class from H723R.
diagnosis:
- name: Temporal Bone Imaging
  description: >-
    CT or MRI demonstrating the enlarged vestibular aqueduct, and with it the
    incomplete cochlear partition and modiolar hypoplasia that often accompany
    it. In practice the combination of audiology and imaging is what makes the
    diagnosis before genetics is available.
  diagnosis_term:
    preferred_term: temporal bone CT or MRI
    term:
      id: NCIT:C16502
      label: Diagnostic Imaging Testing
  evidence:
  - reference: PMID:41066100
    reference_title: Reevaluation of Enlarged Vestibular Aqueduct.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: while 375 of 597 (62.8%) received a diagnosis through combined audiological
      and radiological assessments
    explanation: Quantifies how the diagnosis is actually reached in a large cohort.
- name: SLC26A4 Molecular Testing
  description: >-
    Establishes the diagnosis. A negative coding-region result in a patient with
    the imaging phenotype should raise the CEVA haplotype and structural or
    deep-intronic alleles rather than exclude the gene.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of SLC26A4-SNHL is established in a proband with suggestive findings
      and biallelic pathogenic variants in SLC26A4 identified by molecular genetic testing.
    explanation: The diagnostic criterion as GeneReviews states it.
- name: Perchlorate Discharge Test
  description: >-
    Measures whether iodide taken up by the thyroid has been organified:
    perchlorate displaces un-organified iodide, so a discharge above threshold
    reports a defect. It is what makes the syndromic/nonsyndromic distinction
    demonstrable rather than assumed.

    Two limits are worth stating. The defect is partial, so the test can be
    negative in a genetically confirmed patient - which is part of why iodine-replete
    populations report lower goitre and organification frequencies. And it is not
    specific: siblings with goitre, hypothyroidism, deafness and a positive
    discharge test but no inner-ear malformation have been reported as a
    pseudo-Pendred phenotype, so a positive test does not by itself make the
    diagnosis.
  diagnosis_term:
    preferred_term: laboratory procedure
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  evidence:
  - reference: PMID:11919333
    reference_title: 'Differential diagnosis between Pendred and pseudo-Pendred syndromes:
      clinical, radiologic, and molecular studies.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinically, all patients had goiter with positive perchlorate test, hypothyroidism,
      and severe or profound sensorineural hearing loss.
    explanation: The test used in a genetically characterised series, positive across it.
  - reference: PMID:21274344
    reference_title: "Congenital goitrous hypothyroidism, deafness and iodide organification defect in four siblings: Pendred or pseudo-Pendred syndrome?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we report four siblings who have goiter, severe hypothyroidism, a positive
      perchlorate discharge test and sensorineural deafness, but not the inner ear abnormality
      which is diagnostic for PDS.
    explanation: PARTIAL because it bounds the test rather than supporting it - a positive
      discharge test with the full clinical triad and no inner-ear malformation, which is
      the specificity limit this diagnosis entry records.
treatments:
- name: Audiological and Thyroid Surveillance
  therapeutic_modality: OTHER
  description: >-
    Not treatment but the schedule that makes the rest of management possible.
    Audiometry every three to six months until age three and annually thereafter,
    with thyroid ultrasound from age ten. The audiometric interval is the
    mechanism-relevant part: this is a fluctuating, step-wise loss, so a hearing
    level measured once is not a trajectory, and habilitation has to be re-fitted
    against a moving target.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Audiometric testing every three to six months until age three years and annually
      thereafter; baseline ultrasound to assess thyroid size at age ten years, followed by
      repeat ultrasound every five to ten years based on findings on palpation of thyroid
      size.
    explanation: The GeneReviews surveillance schedule, covering both organs this disease
      affects.
- name: Hearing Habilitation
  therapeutic_modality: DEVICE
  description: >-
    Amplification and multidisciplinary hearing habilitation, which is the
    mainstay and is habilitation rather than treatment of the disease. Early
    auditory intervention is what protects speech and language development, and
    the fluctuating course means the fitting has to be revisited rather than set
    once.
  treatment_term:
    preferred_term: hearing habilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  target_mechanisms:
  - target: Failure to Acquire Normal Hearing
    treatment_effect: BYPASSES
    description: >-
      Amplifies the residual signal. It does nothing to the anion-transport
      lesion.
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Habilitation options tailored to the degree and frequency of hearing loss can
      include hearing aids when hearing loss is mild to severe and consideration of cochlear
      implantation (CI) when hearing aids have had limited benefit.
    explanation: The management algorithm as GeneReviews sets it out, including the
      threshold at which implantation is considered.
- name: Cochlear Implantation
  therapeutic_modality: DEVICE
  description: >-
    Considered where hearing aids have had limited benefit. It carries a
    specific and predictable perioperative issue in this disorder - a perilymph
    gusher - which is a consequence of the inner-ear malformation itself rather
    than of surgical technique, and is the reason the surgeon needs the diagnosis
    beforehand rather than afterwards.
  treatment_term:
    preferred_term: cochlear implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Failure to Acquire Normal Hearing
    treatment_effect: BYPASSES
    description: >-
      Substitutes for the transduction the cochlea can no longer perform,
      stimulating the auditory nerve directly.
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: it is essential that the treating otolaryngologist be aware of the possible
      perioperative complications (most commonly perilymph gusher/oozing) and postoperative
      complications (most commonly transient vertigo) in individuals with SLC26A4-SNHL
    explanation: The disease-specific surgical risk, which is the claim that makes this a
      separate treatment item rather than a line in the habilitation entry.
- name: Levothyroxine for Thyroid Insufficiency
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Replacement where thyroid function is inadequate or to suppress goitre
    growth. It addresses the thyroid arm only; there is no evidence here that it
    alters the hearing, and the developmental window for the inner ear has closed
    long before the goitre appears.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levothyroxine
      term:
        id: NCIT:C62080
        label: Levothyroxine
  target_mechanisms:
  - target: Compensatory Thyroid Stimulation and Goitre
    treatment_effect: MODULATES
    description: >-
      Reduces the TSH drive that produces the enlargement.
  evidence:
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Medical treatment of thyroid enlargement and/or abnormal thyroid function requires
      consultation with
    explanation: PARTIAL because GeneReviews directs the reader to specialist consultation
      rather than specifying an agent - so this item supports that the thyroid arm is
      treated, not that levothyroxine is the specified treatment.
- name: Pendrin Corrector (Investigational)
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    A small-molecule chaperone that restores surface expression of misfolded
    pendrin. In cells, PC2-1 restored both surface expression and anion-exchange
    activity of p.His723Arg, the most common variant in East Asian patients, and
    reached micromolar concentrations in cochlear perilymph in vivo. Preclinical
    only, and by construction it can only help the trafficking class of variants.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Biallelic SLC26A4 Loss of Function
    treatment_effect: RESTORES
    description: >-
      Restores the protein to the membrane where the defect is folding rather
      than transport. It has no target in an anion-binding-site variant.
  evidence:
  - reference: PMID:37690388
    reference_title: Novel small molecule-mediated restoration of the surface expression
      and anion exchange activity of mutated pendrin causing Pendred syndrome and DFNB4.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: These preclinical data support the hypothesis of the druggability of mutant
      pendrin using the novel corrector molecule PC2-1.
    explanation: PARTIAL because the authors present this as preclinical support for
      druggability, not as demonstrated benefit.
- name: Prenatal SLC26A4 Gene Transfer (Investigational)
  therapeutic_modality: GENE_THERAPY
  description: >-
    Electroporation of SLC26A4 cDNA into the otocyst of Slc26a4-knockout mice
    before birth. It prevented endolymphatic enlargement and rescued both hearing
    and vestibular function - the strongest demonstration that the inner-ear
    lesion is preventable if the protein arrives early enough, and the reason the
    therapeutic window is the question the entry's central discussion turns on.
    Prenatal otocyst electroporation is not a route available in human patients.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Biallelic SLC26A4 Loss of Function
    treatment_effect: RESTORES
    description: >-
      Supplies the gene before the critical interval rather than after it.
  evidence:
  - reference: PMID:31784581
    reference_title: Prenatal electroporation-mediated gene transfer restores Slc26a4 knock-out
      mouse hearing and vestibular function.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: supplementation of the target gene cDNA into the otocysts of homozygous Slc24a4
      knockout mice significantly prevented enlargement of the endolymphatic space in the
      inner ear areas; moreover, it rescued hearing and vestibular function of mice in vivo
    explanation: Both the structural and the functional rescue. Note the source's own typo,
      "Slc24a4" for Slc26a4, reproduced as published.
- name: CRISPR Exon Skipping (Investigational)
  therapeutic_modality: GENE_EDITING
  description: >-
    Editing to skip a premature termination codon arising from the c.919-2A>G
    splice variant. Recorded here because its result is informative and negative:
    the edit restored the protein and normal vestibular function, and hearing did
    not improve, with hair cell loss and elevated thresholds on pathology. That is
    a direct counterexample to the assumption that restoring pendrin restores
    hearing whenever it is done, and it concerns the same variant as the family in
    this entry's intrafamilial-variability discussion.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Biallelic SLC26A4 Loss of Function
    treatment_effect: RESTORES
    description: >-
      Restores expression from the mutant allele. The restoration was achieved and
      did not deliver the hearing outcome, which is the finding worth carrying.
  evidence:
  - reference: PMID:39232211
    reference_title: CRISPR/Cas9-mediated exon skipping to restore premature translation
      termination in a DFNB4 mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: However, despite these molecular achievements, hearing function did not show
      the expected improvement, consistent with observed pathology, including cochlear hair
      cell loss and elevated hearing thresholds.
    explanation: PARTIAL because the molecular objective was met and the functional one was
      not. Carried as a negative result rather than omitted, since it constrains what
      restoring pendrin can be expected to achieve and when.
- name: AAV SLC26A4 Gene Replacement (Investigational)
  therapeutic_modality: GENE_THERAPY
  description: >-
    Delivery of SLC26A4 to the endolymphatic sac and cochlear lateral wall. The
    result that matters is that it worked postnatally in a mouse whose auditory
    phenotype resembles the human one, with effects persisting into adulthood -
    because the mouse critical-window data had made prenatal delivery look
    necessary. Whether a comparable postnatal window exists in humans is the
    central open question and is recorded as a knowledge gap.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Biallelic SLC26A4 Loss of Function
    treatment_effect: RESTORES
    description: >-
      Supplies a functional copy of the gene, acting upstream of every node in
      this entry.
  evidence:
  - reference: PMID:41701544
    reference_title: Postnatal Slc26a4 gene therapy improves hearing and structural integrity
      in a hereditary hearing loss model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Comprehensive phenotypic analyses revealed a critical therapeutic window spanning
      the neonatal and juvenile stages, within which AAV.Anc80L65-mediated SLC26A4 delivery
      significantly improved hearing, as evidenced by lower auditory brainstem response thresholds.
    explanation: The postnatal window and the hearing benefit, measured by ABR threshold.
animal_models:
- name: Doxycycline-inducible Slc26a4 transgenic mouse on the Slc26a4-null background
  species: Mouse
  genotype: Slc26a4-null carrying a doxycycline-inducible Slc26a4 transgene
  publication: PMID:21965328
  description: >-
    The model that turned pendrin's requirement into a time interval. All
    functional pendrin comes from the transgene, so expression can be started and
    stopped, and the hearing outcome read against when it was present.
  modeled_mechanisms:
  - target: Endolymphatic Acidification
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Withdrawing pendrin acidifies endolymph and collapses the endocochlear
      potential, establishing the sequence rather than inferring it from a
      constitutive null.
    limitations: >-
      The developmental timing is mouse timing. Mapping E16.5-P2 onto a human
      gestational interval is exactly the step this model cannot make, and it is
      why the therapeutic window in humans is an open question rather than a
      converted date. The constitutive Slc26a4-null mouse, by contrast, is
      profoundly deaf with malformations more severe than the human phenotype,
      so severity in either mouse should not be read across to patients.
    readouts:
    - name: Endocochlear potential
      target: Endolymphatic Acidification
      direction: DECREASED
      interpretation: >-
        The electrophysiological consequence of failed endolymph handling, and
        the step that links the ionic lesion to the sensory one.
      evidence:
      - reference: PMID:21965328
        reference_title: Mouse model of enlarged vestibular aqueducts defines temporal requirement
          of Slc26a4 expression for hearing acquisition.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Lack of pendrin during this period led to endolymphatic acidification,
          loss of the endocochlear potential, and failure to acquire normal hearing.
        explanation: The measured chain including the endocochlear potential.
  evidence:
  - reference: PMID:21965328
    reference_title: Mouse model of enlarged vestibular aqueducts defines temporal requirement
      of Slc26a4 expression for hearing acquisition.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Varying the temporal expression of Slc26a4 revealed that E16.5 to P2 was the
      critical interval in which pendrin was required for acquisition of normal hearing.
    explanation: The result that makes this model informative - a defined interval rather
      than a presence/absence phenotype.
  - reference: PMID:21965328
    reference_title: Mouse model of enlarged vestibular aqueducts defines temporal requirement
      of Slc26a4 expression for hearing acquisition.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Doxycycline initiation at E18.5 or discontinuation at E17.5 resulted in partial
      hearing loss approximating the human EVA auditory phenotype.
    explanation: Establishes that partial timing gives the partial human phenotype, which
      is what makes this model closer to patients than the constitutive null.
- name: Slc26a4 loop/loop mouse
  species: Mouse
  genotype: Slc26a4 loop/loop
  publication: PMID:24760582
  description: >-
    A mouse that is profoundly deaf with a normal-sized thyroid gland, modelling
    the nonsyndromic end of the spectrum, and in which the thyroid nevertheless
    turns out to be histologically abnormal.
  modeled_mechanisms:
  - target: Reduced Local Thyroid Hormone During Inner Ear Development
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Shows atrophic thyroid follicles with normal circulating hormone alongside
      inner-ear defects characteristic of hypothyroidism - the observation the
      cochlear-hypothyroidism reading rests on.
    limitations: >-
      Circulating thyroid hormone was within the normal range, so the model
      demonstrates a histological thyroid abnormality and an inner-ear phenotype
      resembling hypothyroidism, not a measured local hormone deficit in the
      cochlea. The causal step from one to the other is the authors' proposal.
      The mouse also lacks goitre entirely, so it does not model the syndromic
      thyroid phenotype at all.
    readouts:
    - name: Inner hair cell BK channel expression
      target: Reduced Local Thyroid Hormone During Inner Ear Development
      direction: ABOLISHED
      interpretation: >-
        A maturation marker known to be thyroid-hormone-dependent, absent here -
        which is the specific reason the phenotype is read as cochlear
        hypothyroidism rather than as generic inner-ear damage.
      evidence:
      - reference: PMID:24760582
        reference_title: Atrophic thyroid follicles and inner ear defects reminiscent of
          cochlear hypothyroidism in Slc26a4-related deafness.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: the absence of BK channel expression of inner hair cells
        explanation: The measured absence behind this readout.
  evidence:
  - reference: PMID:24760582
    reference_title: Atrophic thyroid follicles and inner ear defects reminiscent of cochlear
      hypothyroidism in Slc26a4-related deafness.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Histological analysis of the thyroid gland revealed defective morphology, with
      a majority of atrophic microfollicles, while measurable thyroid hormone in blood serum
      was within the normal range.
    explanation: Establishes both what the model shows and the limit of what it shows -
      abnormal histology with normal circulating hormone.
environmental:
- name: Dietary iodine intake
  exposure_term:
    preferred_term: exposure to iodine
    term:
      id: ECTO:9000084
      label: exposure to iodine
  description: >-
    Iodine status modifies the thyroid phenotype without touching the inner-ear
    one. Adequate dietary iodine lets a partially defective organification step
    keep up, so goitre is less frequent and less severe where salt is iodised;
    where it is not, the same genotypes present with the goitre that named the
    syndrome. This is why goitre frequency in a cohort describes a food policy as
    much as a gene, and why the syndromic/nonsyndromic label can differ between
    populations carrying identical variants.
  evidence:
  - reference: PMID:28648509
    reference_title: Pendred syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The thyroid phenotype is variable and may be modified by the nutritional iodine
      intake.
    explanation: The exposure claim at entry level - that nutritional iodine is a modifier
      of the thyroid phenotype in this disease, which is what makes it worth recording as
      an exposure at all.
  - reference: PMID:20301640
    reference_title: SLC26A4-Related Sensorineural Hearing Loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Thyroid enlargement (goiter) occurs gradually and is typically evident in the
      second decade, especially if iodine is not routinely included in the diet.
    explanation: The dietary condition stated in the GeneReviews clinical description,
      independent of the mechanism link below.
  influences_mechanisms:
  - target: Compensatory Thyroid Stimulation and Goitre
    environmental_effect: MODULATES
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Sufficient iodide supply raises the substrate available to a partially
      impaired organification step, reducing the TSH drive that produces glandular
      enlargement. Recorded as MODULATES rather than PROTECTS_AGAINST because the
      sources state that the thyroid phenotype is modified by iodine intake, not
      that iodine prevents the goitre.
    evidence:
    - reference: PMID:28648509
      reference_title: Pendred syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The thyroid phenotype is variable and may be modified by the nutritional iodine
        intake.
      explanation: States the modification directly, and in the hedged form the link's
        predicate is chosen to match.
    - reference: PMID:20301640
      reference_title: SLC26A4-Related Sensorineural Hearing Loss.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Thyroid enlargement (goiter) occurs gradually and is typically evident in the
        second decade, especially if iodine is not routinely included in the diet.
      explanation: The dietary condition under which the goitre is expected, from the
        GeneReviews clinical description.
discussions:
- discussion_id: pendred_human_therapeutic_window_unknown
  kind: HUMAN_MODEL_MISMATCH
  attaches_to:
  - animal_models#Doxycycline-inducible Slc26a4 transgenic mouse on the Slc26a4-null background
  - treatments#AAV SLC26A4 Gene Replacement (Investigational)
  prompt: Does the postnatal therapeutic window demonstrated in mice exist in humans, and
    when does it close?
  rationale: >-
    This is the question on which every disease-modifying therapy for Pendred
    syndrome depends, and the mouse data point two ways at once.

    The conditional model established a narrow interval, E16.5 to P2, in which
    pendrin has to be present for hearing to be acquired. In mouse developmental
    terms much of that is prenatal, and read straight across it implies that
    intervention in a human would have to be prenatal too - which would make the
    therapy close to undeliverable. The gene-therapy study then found a
    postnatal-to-juvenile window in which AAV delivery still improved auditory
    brainstem response thresholds, preserved hair cells and partially restored the
    endocochlear potential, with the effect persisting into adulthood.

    Both results are in mice, and mouse and human cochlear maturation are not on
    the same schedule relative to birth: the human cochlea is functionally mature
    considerably earlier in relative terms than the mouse cochlea is. So neither
    result converts into a human date. The specific unknown is not whether
    restoring pendrin helps - that is established in the model - but whether any
    interval after human birth retains the plasticity the mouse experiments
    exploit.

    This is recorded as a HUMAN_MODEL_MISMATCH rather than a plain knowledge gap
    because the evidence is not absent. It exists, it is positive, and its
    translational validity to human disease is precisely what is unresolved.
  evidence:
  - reference: PMID:21965328
    reference_title: Mouse model of enlarged vestibular aqueducts defines temporal requirement
      of Slc26a4 expression for hearing acquisition.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Varying the temporal expression of Slc26a4 revealed that E16.5 to P2 was the
      critical interval in which pendrin was required for acquisition of normal hearing.
    explanation: The mouse critical interval, most of which is prenatal.
  - reference: PMID:41701544
    reference_title: Postnatal Slc26a4 gene therapy improves hearing and structural integrity
      in a hereditary hearing loss model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: While gene therapy holds great potential, its postnatal application has remained
      unexplored because of the lack of suitable animal models and the challenges of prenatal
      intervention.
    explanation: The authors' own framing of why the postnatal question was open, which is
      the mismatch this discussion records.
  - reference: PMID:31784581
    reference_title: Prenatal electroporation-mediated gene transfer restores Slc26a4 knock-out
      mouse hearing and vestibular function.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: it rescued hearing and vestibular function of mice in vivo
    explanation: The prenatal arm of the same question. Delivering the gene before the
      critical interval works; that it works there is what made the postnatal result
      surprising and what makes the human window the open question rather than a settled
      one.
  - reference: PMID:39232211
    reference_title: CRISPR/Cas9-mediated exon skipping to restore premature translation
      termination in a DFNB4 mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: However, despite these molecular achievements, hearing function did not show
      the expected improvement, consistent with observed pathology, including cochlear hair
      cell loss and elevated hearing thresholds.
    explanation: PARTIAL, and included because it cuts against the optimistic reading -
      restoring the protein is not sufficient once the structural damage is present, which
      is the same window constraint approached from the failure side.
- discussion_id: pendred_variant_class_determines_therapy
  kind: INTERPRETATION
  attaches_to:
  - pathophysiology#Biallelic SLC26A4 Loss of Function
  - treatments#Pendrin Corrector (Investigational)
  prompt: Why does it matter whether a SLC26A4 variant abolishes transport or abolishes
    trafficking?
  rationale: >-
    Clinically the two look the same - no pendrin function, same hearing loss.
    Mechanistically they are different lesions, and the difference decides which
    of the emerging therapies could ever work for a given patient.

    A variant at the anion-binding site or in the transport gate produces a
    protein that reaches the apical membrane and cannot move anions. Nothing that
    improves its delivery helps. A variant such as p.His723Arg produces a protein
    that would work if it arrived, and is instead retained in the endoplasmic
    reticulum; restoring its surface expression restored its exchange activity in
    cells, which is the demonstration that the protein itself is competent.

    This is why the entry curates the two routes inside one pathophysiology node
    rather than collapsing them into "loss of function", and why the corrector's
    target_mechanisms link points at that node with an explicit statement that it
    has no target in a transport-dead variant. It also sets the scope of the
    corrector approach: p.His723Arg is the most common variant in East Asian
    populations, so a chaperone strategy is far more relevant to some populations
    than others.
  evidence:
  - reference: PMID:37690388
    reference_title: Novel small molecule-mediated restoration of the surface expression
      and anion exchange activity of mutated pendrin causing Pendred syndrome and DFNB4.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We observed that pendrin corrector (PC2-1) increased the surface expression
      and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic
      variant that causes Pendred syndrome and DFNB4.
    explanation: Shows surface expression and function restored together, which is what
      identifies this variant as a trafficking rather than a transport lesion.
- discussion_id: pendred_intrafamilial_variability
  kind: KNOWLEDGE_GAP
  attaches_to:
  - genetic#SLC26A4
  - phenotypes#Enlarged Vestibular Aqueduct
  prompt: Why do relatives with the same SLC26A4 genotype have different inner-ear
    morphology?
  rationale: >-
    Within a single family carrying one SLC26A4 variant, inner-ear morphology can
    differ between affected members. Since genotype, and largely environment, are
    held constant, the variation has to come from somewhere else: unidentified
    modifier loci, or stochastic variation in a developmental process that has
    only a narrow window in which to go right.

    The second possibility is not a fallback explanation. This entry's central
    mechanistic claim is that the inner-ear lesion is developmental and
    window-bounded, and a process constrained to a short interval is exactly the
    kind that produces variable outcomes from identical inputs. If that is what is
    happening, then genotype will never predict inner-ear morphology well, and
    effort spent looking for modifiers would be better spent on the natural
    history.

    Distinguishing the two matters for counselling, since one implies a
    predictable familial pattern and the other does not.
  evidence:
  - reference: PMID:38877731
    reference_title: Variability in Inner Ear Morphology Among a Family With Pendred Syndrome
      Due to a SLC26A4 Gene Variant.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We present a family of 4, all of whom possess sensorineural hearing loss due
      to the same homozygous SLC26A4 variant c.919-2A>G. Intriguingly, clinical manifestations,
      especially inner ear deformities, displayed variability among family members.
    explanation: The observation itself - one homozygous variant, four affected relatives,
      differing inner-ear morphology - which is what makes the variability a genotype-held-constant
      finding rather than an impression.
references:
- reference: PMID:9398842
  title: Pendred syndrome is caused by mutations in a putative sulphate transporter gene
    (PDS).
- reference: PMID:20301640
  title: SLC26A4-Related Sensorineural Hearing Loss.
  tags:
  - GeneReviews
- reference: PMID:21965328
  title: Mouse model of enlarged vestibular aqueducts defines temporal requirement of Slc26a4
    expression for hearing acquisition.
- reference: PMID:22116353
  title: Transcriptional regulation of the pendrin gene.
- reference: PMID:24760582
  title: Atrophic thyroid follicles and inner ear defects reminiscent of cochlear hypothyroidism
    in Slc26a4-related deafness.
- reference: PMID:28648509
  title: Pendred syndrome.
- reference: PMID:30634102
  title: Hearing loss in unilateral and bilateral enlarged vestibular aqueduct syndrome.
- reference: PMID:34345941
  title: Genetic architecture and phenotypic landscape of SLC26A4-related hearing loss.
- reference: PMID:37690388
  title: Novel small molecule-mediated restoration of the surface expression and anion exchange
    activity of mutated pendrin causing Pendred syndrome and DFNB4.
- reference: PMID:38877731
  title: Variability in Inner Ear Morphology Among a Family With Pendred Syndrome Due to
    a SLC26A4 Gene Variant.
- reference: PMID:41066100
  title: Reevaluation of Enlarged Vestibular Aqueduct.
- reference: PMID:41701544
  title: Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary
    hearing loss model.
notes: >-
  Scope. Pendred syndrome and DFNB4 are curated here as subtypes of one entry
  rather than as two entries. They share the gene, the inner-ear mechanism and the
  allelic spectrum; what separates the labels is whether a thyroid organification
  defect is demonstrable, and that is modified by dietary iodine. Splitting them
  would duplicate the whole pathograph to record one branch.

  Frequencies. The cohort numbers quoted here come from a 2774-patient Chinese
  EVA cohort and are labelled as such in their evidence explanations rather than
  presented as disease frequencies. The 6.4% goitre figure in particular is
  graded PARTIAL: it measures goitre in an EVA cohort in a salt-iodised
  population, which is close to the opposite of the population in which Pendred
  syndrome's thyroid phenotype is most penetrant.

  Ontology terms. GO has no term for the endocochlear potential or for
  endolymph composition, so those nodes carry no descriptor binding and the
  claims live in the node description. The transport node carries the antiporter
  activity as a molecular function (GO:0140829) and the bicarbonate secretion as
  a biological process (GO:0015701); the iodide arm is captured by the
  chemical_entities binding rather than by a second process term.

  Two terms had to be changed because they exist but are not members of the
  schema's dynamic enum for the slot, which is a distinct failure from a term not
  existing. GO:0015701 is a real term and a wrong molecular function, since
  bicarbonate transport is a process; it was moved to biological_processes and
  the molecular function rebound to GO:0140829. NCIT:C157820 (Cochlear Implant)
  is a real term for the device, not for the clinical action, so it is not
  reachable from NCIT:C25218 and fails the TreatmentActionTerm enum; the
  implantation treatment is bound to NCIT:C15329 (Surgical Procedure) with
  preferred_term carrying the specific reading. Both were caught by
  just validate-terms rather than by inspection.

  Deep research. An openscientist run was commissioned and was substantially
  useful: all thirteen PMIDs taken from it resolved to the titles the report gave
  them when fetched with just fetch-reference, and its independently-derived
  causal model matched the one curated here, including the dual inner-ear route
  through cochlear hypothyroidism.

  What the report got wrong, and it is worth recording because these are the
  failure modes a curator has to catch. Its own term-validation section flagged
  one invented CL identifier, CL:1000722 for a beta-intercalated cell, which does
  not exist. It also proposed UBERON:0002518 for the endolymphatic sac; that
  CURIE resolves, but to "otolith organ", so nothing in the validation output
  marked it as wrong. The correct term, UBERON:0002223, was found by searching
  the ontology rather than by trusting the report. That is the more dangerous of
  the two errors: a fabricated identifier fails validation, whereas a real
  identifier for the wrong concept passes every automated check there is.

  Three off-topic caches. references_cache/PMID_11734249.md (the American Red
  Cross), PMID_15347930.md (dental veneering composites) and PMID_17997835.md
  (riboswitches) are committed here and have nothing to do with this disease.
  They came from an early attempt to fetch remembered PMIDs for known Pendred
  papers - the identifiers were wrong, the fetch returned whatever those numbers
  actually point at, and the titles made that obvious immediately. They are
  recorded here so they read as checked and discarded rather than overlooked, and
  as the reason every PMID in this entry was afterwards located by search rather
  than from memory.

  A snippet self-check that the gates caught. The intrafamilial-variability
  evidence item initially quoted only the paper's title phrase, with an
  explanation admitting it was weak. just check-snippet-length and
  just check-title-snippets both rejected it, correctly and without a
  grandfathering escape, and re-reading the cache showed the abstract carries a
  proper sentence stating the finding. The lesson is the reverse of the usual
  one: the defect was not that the source was inadequate but that the cache had
  not been read carefully enough before writing the snippet.
📚

References & Deep Research

References

12
PMID:9398842
Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS).
No top-level findings curated for this source.
PMID:20301640
SLC26A4-Related Sensorineural Hearing Loss.
No top-level findings curated for this source.
PMID:21965328
Mouse model of enlarged vestibular aqueducts defines temporal requirement of Slc26a4 expression for hearing acquisition.
No top-level findings curated for this source.
PMID:22116353
Transcriptional regulation of the pendrin gene.
No top-level findings curated for this source.
PMID:24760582
Atrophic thyroid follicles and inner ear defects reminiscent of cochlear hypothyroidism in Slc26a4-related deafness.
No top-level findings curated for this source.
PMID:28648509
Pendred syndrome.
No top-level findings curated for this source.
PMID:30634102
Hearing loss in unilateral and bilateral enlarged vestibular aqueduct syndrome.
No top-level findings curated for this source.
PMID:34345941
Genetic architecture and phenotypic landscape of SLC26A4-related hearing loss.
No top-level findings curated for this source.
PMID:37690388
Novel small molecule-mediated restoration of the surface expression and anion exchange activity of mutated pendrin causing Pendred syndrome and DFNB4.
No top-level findings curated for this source.
PMID:38877731
Variability in Inner Ear Morphology Among a Family With Pendred Syndrome Due to a SLC26A4 Gene Variant.
No top-level findings curated for this source.
PMID:41066100
Reevaluation of Enlarged Vestibular Aqueduct.
No top-level findings curated for this source.
PMID:41701544
Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary hearing loss model.
No top-level findings curated for this source.

Deep Research

1
OpenScientist ▸
Pendred Syndrome: Comprehensive Disease Characteristics Report
openscientist-autonomous 18 citations 2026-08-28T16:37:13.930998

Pendred Syndrome: Comprehensive Disease Characteristics Report

Disease: Pendred Syndrome MONDO ID: MONDO:0008550 · OMIM: #274600 · Orphanet: ORPHA 705 Category: Mendelian (autosomal recessive) Report type: Aggregated disease-level knowledge synthesis (literature-derived; not individual EHR)

Summary

Pendred syndrome (PDS) is an autosomal recessive disorder caused by biallelic loss-of-function variants in SLC26A4 (chromosome 7q22.3), which encodes pendrin, a homodimeric 14-transmembrane Cl⁻/HCO₃⁻/I⁻ anion exchanger bearing a cytoplasmic membrane-targeting STAS domain. Pendrin is expressed at the apical membrane of epithelial cells in the inner ear, thyroid, and kidney (and airways), where it mediates endolymph ion/pH balance, thyroid iodide organification, and renal bicarbonate handling respectively. The disease is defined by a classic triad: bilateral sensorineural hearing loss (SNHL), an inner-ear malformation (enlarged vestibular aqueduct [EVA] / incomplete partition type II), and thyroid goiter with an iodide organification defect (positive perchlorate discharge test). PDS is allelic with the nonsyndromic deafness DFNB4; the presence of a thyroid organification defect/goiter distinguishes PDS from DFNB4. Estimated prevalence is 7.5–10 per 100,000 in non-African populations.

Mechanistically, pendrin loss abolishes HCO₃⁻ secretion into endolymph during a defined perinatal developmental window (mapped in mouse to E16.5–P2), causing endolymphatic acidification, loss of the endocochlear potential, enlargement of the endolymphatic compartment (EVA), and failure to acquire normal hearing. A second, thyroid-hormone-dependent inner-ear component—resembling local cochlear hypothyroidism—also contributes to the deafness phenotype. In the thyroid, impaired apical iodide efflux limits iodide organification, producing euthyroid or hypothyroid goiter. Genotype correlates with severity along an M2 (biallelic coding/splice) > M1 + CEVA haplotype > M0 gradient, and the mutation spectrum is strongly population-specific (e.g., H723R and IVS15+5G>A in Japanese/Okinawan cohorts).

Clinically, PDS is non-life-limiting; the dominant burden is progressive/fluctuating deafness and its effect on communication and quality of life. Current management is supportive (hearing aids, cochlear implantation, levothyroxine for hypothyroidism, avoidance of head trauma, and genetic counseling). Excitingly, multiple preclinical therapeutic strategies—postnatal AAV gene replacement, CRISPR/Cas9 exon-skipping, small-molecule pendrin "correctors" (e.g., PC2-1 for H723R), and prenatal electroporation gene transfer—rescue pendrin function within an early therapeutic window, opening a realistic path to disease modification.

Section 1 — Disease Information

Overview. Pendred syndrome is a Mendelian, autosomal recessive multi-organ disorder combining congenital/early-onset sensorineural hearing loss, a characteristic inner-ear malformation (EVA), and thyroid dyshormonogenesis (goiter with iodide organification defect). It was first described by Vaughan Pendred in 1896 and molecularly resolved with the identification of SLC26A4 (originally PDS).

Key identifiers.

Resource Identifier
OMIM #274600
MONDO MONDO:0008550
Orphanet ORPHA 705
Gene (HGNC) SLC26A4
Gene locus 7q22.3
Allelic nonsyndromic disorder DFNB4 (OMIM #600791)
ICD-10 E07.1 (dyshormonogenetic goiter) / H90.x (SNHL); commonly coded jointly
MeSH Pendred Syndrome (D053576)

Synonyms / alternative names: Pendred's syndrome; deafness with goiter; goiter-deafness syndrome; thyroid hormone organification defect IIB; autosomal recessive sensorineural hearing impairment with goiter.

Data provenance: This report is derived from aggregated disease-level resources (OMIM, Orphanet, primary literature, model-organism studies), not from individual patient EHR data.

Supporting evidence: "Pendred syndrome (PDS) is an autosomal recessive disease caused by variants in SLC26A4 manifesting thyroid dyshormonogenesis. Patients typically present with goiter and sensorineural hearing loss (SNHL). The prevalence of PDS in non-African populations is estimated to be between 7.5 and 10 per 100,000" — PMID: 40956475. "A thyroid iodine organification defect can lead to multinodular goiter and distinguishes Pendred syndrome from DFNB4. Pendred syndrome and DFNB4 are each inherited as an autosomal recessive trait caused by biallelic mutations of SLC26A4." — PMID: 34345941.

Section 2 — Etiology

Primary cause (genetic). PDS is a monogenic disorder caused by biallelic pathogenic variants in SLC26A4. It is not infectious, autoimmune, or primarily environmental. (Note: a mimicking condition, "pseudo-Pendred syndrome"—goiter + deafness without inner-ear malformation and without SLC26A4 mutations, potentially autoimmune or TPO-related—is a distinct entity and should be excluded; PMID: 21274344.)

Genetic risk factors / genotype classes. Disease expression follows a genotype gradient: - M2 — two mutant SLC26A4 alleles (coding/splice) → full phenotype, most severe. - M1 + CEVA — one coding/splice mutation in trans with the Caucasian EVA (CEVA) haplotype (12 upstream variants acting as a hypomorphic recessive allele) → milder phenotype. - M0 — no detectable SLC26A4 mutation → low sibling recurrence; alternative genetic causes (e.g., CHD7, FOXI1, KCNJ10, or digenic mechanisms).

Environmental / modifying factors. Iodine status/diet modulates thyroid phenotype severity (iodide organification defect is more clinically apparent under iodine stress). Head trauma / barotrauma / pressure changes can precipitate sudden hearing-loss drops or vertigo in EVA. Consanguinity raises recurrence risk in populations with high intermarriage rates (e.g., Iran, Pakistan, Sudan).

Protective factors. No robust protective genetic alleles are established. Environmentally, adequate dietary iodine and avoidance of head/barotrauma reduce, respectively, thyroid decompensation and acute hearing drops.

Gene–environment interactions. The best-characterized interaction is genotype × iodine intake shaping goiter/hypothyroidism penetrance, and genotype × mechanical/pressure trauma shaping the timing of hearing-loss progression.

"In most European-Caucasian M1 patients, there is a haplotype … called CEVA (Caucasian EVA), which acts as a pathogenic recessive allele in trans to mutations affecting the coding regions or splice sites of SLC26A4. This combination … is associated with a less severe phenotype than the M2 genotype." — PMID: 34345941.

Section 3 — Phenotypes

Phenotype Type HPO term (suggested) Onset Severity Progression Frequency
Sensorineural hearing loss (bilateral) Clinical sign HP:0000407 (SNHL); HP:0008619 (bilateral SNHL) Congenital–childhood; may pass newborn screen and present later Moderate–profound; variable Progressive, often fluctuating/step-wise ~All affected
Enlarged vestibular aqueduct Imaging manifestation HP:0011387 Congenital n/a (structural) Stable structure ~96% of EVA cohorts carry biallelic SLC26A4
Incomplete partition type II / Mondini Imaging manifestation HP:0011389 (inner ear malformation) Congenital Variable Stable Frequent
Goiter Clinical sign HP:0000853 (goiter); HP:0000821 (hypothyroidism) Childhood–young adult (often peripubertal) Mild–moderate; euthyroid or hypothyroid Progressive/nodular ~6.4% in a large EVA cohort; higher in classic PDS series
Vertigo / vestibular dysfunction Symptom HP:0002321 (vertigo); HP:0000365 (hearing impairment) Childhood–adult Variable, episodic Episodic/recurrent ~42.9% recurrent vertigo in EVA cohort
Iodide organification defect (perchlorate discharge +) Laboratory abnormality HP:0031428 (abnormal thyroid physiology) Congenital (biochemical) n/a Stable Characteristic of PDS vs DFNB4

Quality-of-life impact. The dominant QoL burden is communicative: progressive/fluctuating bilateral SNHL affects language acquisition (if early), education, employment, and social participation. Episodic vertigo adds functional/balance disability. Goiter/hypothyroidism carries the usual metabolic and cosmetic/compressive burden when present. Notably, 36.4% of one EVA subset passed newborn hearing screening, underscoring later-onset/progressive loss that can be missed at birth and delay intervention.

"Recurrent vertigo (256 of 597 [42.9%]) and goiter (38 of 597 [6.4%]) were common comorbidities." — PMID: 41066100.

Section 4 — Genetic / Molecular Information

Causal gene. SLC26A4 (7q22.3; OMIM *605646), encoding pendrin. It is the single major causal gene for PDS and allelic DFNB4.

Pathogenic variants. - Types: missense (e.g., p.His723Arg / H723R, p.Thr410Met), nonsense (p.Trp482 / p.Trp482X), frameshift (e.g., c.2260del/p.Asp754Ilefs5), splice-site (c.919-2A>G/IVS7-2A>G; IVS15+5G>A), and structural/copy-number variants; also a deep-intronic splicing variant c.304+941C>T. - Classification: Per ACMG/AMP, many recurrent alleles are Pathogenic/Likely Pathogenic; functional assays (iodide influx, surface expression, confocal localization) are frequently needed to reclassify VUS. Functional testing confirmed pathogenicity for novel variants including p.G139R, p.M147I, p.Y530S, p.D754Ifs5, and p.F161I (PMID: 40426046). - Functional consequence: predominantly loss of function — impaired anion exchange and/or defective apical membrane trafficking (misfolding/ER retention, as for H723R). - Origin: germline (recessive, inherited). No somatic contribution. - Allele frequency:* individual pathogenic alleles are rare in gnomAD; specific alleles are enriched by founder effects (below).

Population-specific spectrum (founder effects).

Population Predominant alleles Note
Japanese / Okinawan H723R, IVS15+5G>A ~90% of alleles in Okinawa
Sudanese (consanguineous) p.Thr410Met, p.Trp482* Congenital hypothyroidism families
Iranian deaf cohorts Multiple (c.919-2A>G, etc.) SLC26A4 ~8–16% of NSHL
European Caucasian Coding/splice + CEVA haplotype ~50% of EVA are M0/M1

Modifier genes / genetic heterogeneity. In EVA without biallelic SLC26A4, monoallelic CHD7 variants (CHARGE-associated gene) can cause nonsyndromic EVA (PMID: 37668839); FOXI1 and KCNJ10 have been proposed in digenic models. The CEVA upstream haplotype is the principal validated modifier of severity.

Epigenetic / chromosomal. No recurrent disease-defining epigenetic marks or gross chromosomal aberrations are established for PDS; disease is at the single-gene level. Transcriptional regulation of the pendrin gene has been characterized (PMID: 22116353), but methylation-based mechanisms are not a recognized cause. Copy-number variants (~2.5% of one EVA cohort) are the main large-scale change.

"Genetic analysis revealed that 2661 of 2774 patients (95.9%) carried biallelic SLC26A4 variants, with 70 (2.5%) attributable to copy number variants and 13 (0.5%) to a deep-intronic variant (c.304 + 941C>T) that affected splicing." — PMID: 41066100. "The most prevalent types of SLC26A4 alleles were IVS15 + 5G > A and H723R" — PMID: 23705809.

Section 5 — Environmental Information

  • Environmental factors: Dietary iodine is the key modulator of the thyroid phenotype; iodine deficiency exacerbates goiter/organification stress. No toxin, radiation, or occupational exposure causes PDS.
  • Lifestyle / physical factors: Head trauma, barotrauma, and activities with pressure changes (contact sports, diving) are associated with sudden hearing drops/vertigo in EVA and are advised against.
  • Infectious agents: None. PDS is genetic; infectious deafness (e.g., congenital CMV) is a differential, not a cause.

Section 6 — Mechanism / Pathophysiology

Molecular/biochemical core. Pendrin (SLC26A4) is an electroneutral apical Cl⁻/HCO₃⁻/I⁻ anion antiporter of the SLC26/SulP family. It mediates bicarbonate secretion / chloride reabsorption (inner ear and kidney), iodide accumulation/efflux (thyroid apical membrane), and endolymph ion balance (inner ear). It functionally partners with CFTR in epithelial anion transport.

Structural basis of dysfunction. Pendrin is a homodimer with a 14-transmembrane core arranged in an elevator-type transport architecture (mobile core + gate domains) and a C-terminal cytoplasmic STAS domain (Sulfate Transporter and Anti-Sigma factor antagonist; conserved 4 β-strand / 5 α-helix fold). A basic residue at the anion-binding site is essential for anion antiport, and STAS-domain integrity is essential for membrane targeting; STAS mutations are disease-associated. Disease variants act by (i) abolishing transport (anion-binding/gate residues) or (ii) mistrafficking/ER retention (e.g., H723R), reducing surface expression.

Inner-ear causal chain (dual mechanism).

SLC26A4 LoF
   │
   ├─►  Loss of apical HCO3- secretion into endolymph
   │        │  (critical window: mouse E16.5–P2)
   │        ▼
   │    Endolymphatic ACIDIFICATION  ──►  loss of endocochlear potential
   │        │                                    │
   │        ▼                                    ▼
   │    Enlarged endolymphatic sac/duct  →  EVA   Hair-cell dysfunction / failure to
   │                                              acquire normal hearing → SNHL (progressive/fluctuating)
   │
   └─►  Reduced LOCAL thyroid-hormone availability during inner-ear development
    ▼
"Cochlear hypothyroidism"-like defects:
thick tectorial membrane (↓β-tectorin), absent BK channel in inner hair cells,
reduced inner-ear bone calcification  ──►  contributes to deafness
  • Upstream trigger: loss of pendrin-mediated HCO₃⁻ transport during the perinatal window.
  • Downstream manifestations: endolymph acidification → loss of endocochlear potential → hair-cell dysfunction → SNHL; and endolymphatic enlargement → EVA.
  • Parallel contributor: insufficient local thyroid hormone during inner-ear development (cochlear-hypothyroidism-like phenotype).

Thyroid causal chain. Apical pendrin normally supports iodide efflux into the follicular lumen for organification by TPO/H₂O₂. Loss → impaired iodide organification → compensatory TSH rise → goiter, with euthyroidism or (partial) hypothyroidism; positive perchlorate discharge test.

Cell types & processes involved (ontology suggestions): - Inner-ear: endolymphatic sac/duct epithelial cells, cochlear lateral wall (stria vascularis) cells, inner hair cells (CL:0000589), outer hair cells (CL:0000601). - Thyroid: thyroid follicular cell / thyrocyte (CL:0002258). - Kidney: β-intercalated cell of cortical collecting duct (CL:1000722). - Processes (GO): GO:0006820 anion transport; GO:0015701 bicarbonate transport; GO:0006821 chloride transport; inner-ear development GO:0048839; ion homeostasis/endocochlear-potential maintenance. - Cellular components (GO CC): GO:0016324 apical plasma membrane; GO:0005886 plasma membrane; GO:0005783 endoplasmic reticulum (mistrafficked mutants). - Chemical entities (CHEBI): bicarbonate (CHEBI:17544), chloride (CHEBI:17996), iodide (CHEBI:16382).

Immune/metabolic involvement. No autoimmune mechanism in true PDS. Metabolic change is limited to thyroid hormone economy. Notably, elevated SLC26A4 expression is implicated in airway inflammation in asthma (a separate, gain-of-expression context), illustrating pendrin's broader epithelial roles (PMID: 39100210).

"Pendrin (SLC26A4), a Cl(-)/anion exchanger encoded by the gene PDS, is highly expressed in the kidney, thyroid and inner ear epithelia and is essential for bicarbonate secretion/chloride reabsorption, iodide accumulation and endolymph ion balance, respectively." — PMID: 22116353. "Lack of pendrin during this period led to endolymphatic acidification, loss of the endocochlear potential, and failure to acquire normal hearing." — PMID: 21965328. "The pathological inner ear hallmarks included thicker tectorial membrane with reduced β-tectorin protein expression, the absence of BK channel expression of inner hair cells, and reduced inner ear bone calcification." — PMID: 24760582. "the basic residue at the anion binding site is essential for both anion antiport of SLC26A4 and motor functions of SLC26A5" — PMID: 38582450.

Section 7 — Anatomical Structures Affected

Organ level (primary): Inner ear (cochlea + vestibular apparatus) and thyroid gland. Secondary/other: kidney (subclinical acid–base handling), airway epithelium (physiological expression). Body systems: special sensory (auditory/vestibular), endocrine (thyroid).

Tissue/cell level: epithelial tissue is the target throughout — endolymphatic sac/duct epithelium and cochlear lateral wall (inner ear), follicular epithelium (thyroid), collecting-duct intercalated cells (kidney).

Subcellular: apical plasma membrane (GO:0016324) — site of pendrin function; ER (GO:0005783) is implicated where trafficking-defective mutants (e.g., H723R) are retained.

Localization (UBERON suggestions): inner ear UBERON:0001690; cochlea UBERON:0001844; vestibular aqueduct/endolymphatic duct UBERON:0002279; endolymphatic sac UBERON:0002518; thyroid gland UBERON:0002046; kidney UBERON:0002113.

Lateralization: Hearing loss and EVA are typically bilateral, but unilateral EVA occurs. Importantly, hearing-loss severity does not differ significantly between unilateral and bilateral EVA.

"No significant differences across bilateral status were observed in audiological measurements." — PMID: 30634102.

Section 8 — Temporal Development

  • Onset: Congenital or early-childhood SNHL; a substantial fraction is later-onset/progressive and can pass newborn hearing screening (36.4% in one subset). Goiter typically emerges in later childhood to young adulthood (often peripubertal).
  • Onset pattern: Insidious/chronic for hearing (with acute "drops"), chronic for goiter.
  • Progression: Hearing loss is progressive and characteristically fluctuating/step-wise, sometimes precipitated by minor head trauma or pressure change. EVA itself is a stable structural malformation.
  • Course/duration: Chronic, lifelong. No spontaneous remission of hearing loss (drops may partially recover but overall trajectory is downward).
  • Critical periods: The perinatal window (mouse E16.5–P2) is the mechanistic critical period for hearing acquisition and the key therapeutic opportunity window for gene/pharmacologic rescue.

"Varying the temporal expression of Slc26a4 revealed that E16.5 to P2 was the critical interval in which pendrin was required for acquisition of normal hearing." — PMID: 21965328.

Section 9 — Inheritance and Population

  • Epidemiology: Prevalence ~7.5–10 per 100,000 (non-African populations). SLC26A4 accounts for a large share of syndromic and EVA-associated deafness; in a 21-year EVA cohort (n=2774), 95.9% carried biallelic SLC26A4 variants.
  • Inheritance: Autosomal recessive.
  • Penetrance: High for hearing loss with biallelic (M2) genotypes; goiter penetrance is incomplete and age/iodine-dependent.
  • Expressivity: Variable, even within families sharing an identical genotype — e.g., a family homozygous for c.919-2A>G showed variable inner-ear morphology, including one member with normal cochleovestibular structure (PMID: 38877731).
  • Genetic anticipation: None (not a repeat-expansion disorder).
  • Germline mosaicism: Not a recognized feature.
  • Founder effects / consanguinity: Strong founder alleles (Okinawa H723R/IVS15+5G>A; Sudanese T410M/W482X). Consanguinity elevates prevalence in the Middle East/South Asia/North Africa.
  • Carrier frequency: Elevated in founder/consanguineous populations; individual alleles rare in outbred populations.
  • Sex ratio: Approximately equal (autosomal recessive); no strong sex predilection.
  • Geographic distribution: Worldwide; specific alleles regionally clustered. Syndromic causes including Pendred are comparatively uncommon in native sub-Saharan African deafness (PMID: 28642064).

"Genetic analysis revealed that 2661 of 2774 patients (95.9%) carried biallelic SLC26A4 variants." — PMID: 41066100.

Section 10 — Diagnostics

Clinical / laboratory tests. - Thyroid function: TSH, free T4 (often euthyroid; may show subclinical/overt hypothyroidism), thyroglobulin. - Perchlorate discharge test: positive — demonstrates the iodide organification defect (the biochemical hallmark distinguishing PDS from DFNB4). - Audiometry: pure-tone audiometry (air/bone), speech recognition threshold (SRT), word recognition score (WRS); OAE/ABR in infants. - Vestibular testing: as indicated for vertigo.

Imaging (definitive for EVA). High-resolution temporal-bone CT and/or MRI demonstrate EVA and associated cochlear incomplete partition type II. EVA is a radiologic diagnosis using the Valvassori criterion (midpoint diameter >1.5 mm) or the more sensitive Cincinnati criterion (>0.9 mm at midpoint and/or >1.9 mm at operculum). Thyroid ultrasound characterizes goiter/nodularity.

Genetic testing (recommended approach). - Single-gene / targeted: SLC26A4 sequencing (plus CEVA haplotype and CNV/deep-intronic analysis) is first-line given the strong genotype correlation. - Panels/WES/WGS: deafness gene panels or exome/genome when SLC26A4 is negative (to detect CHD7, FOXI1, KCNJ10, and others), and to resolve M1/M0 cases; CNV and deep-intronic (c.304+941C>T) detection require appropriate methods (MLPA/CMA/genome or RNA-based confirmation). - Functional confirmation: iodide-influx and surface-expression assays reclassify novel/VUS alleles (PMID: 40426046).

Clinical criteria. Diagnosis rests on the triad (SNHL + EVA/inner-ear malformation + goiter/organification defect) supported by biallelic SLC26A4. Differential diagnosis: DFNB4 (same gene, no organification defect), pseudo-Pendred (autoimmune/TPO; no EVA), CHARGE/CHD7-related EVA, BOR syndrome, congenital CMV, Waardenburg, Usher (progressive), and other dyshormonogenetic goiters.

Screening. Newborn hearing screening (may miss later-onset cases), cascade/carrier testing in families, and prenatal/preimplantation options where a familial genotype is known.

"Using Cincinnati criteria, 89 ears fit inclusion criteria, 75 of which were from patients with bilateral EVA compared to 14 ears from patients with unilateral EVA." — PMID: 30634102.

Section 11 — Outcome / Prognosis

  • Survival/mortality: PDS is not life-limiting; normal life expectancy. No disease-specific mortality.
  • Morbidity/function: Principal morbidity is progressive bilateral SNHL with communication disability; episodic vertigo (≈43% recurrent in EVA cohorts) adds balance disability; goiter/hypothyroidism when present.
  • Disease course: Chronic, lifelong; fluctuating hearing with step-wise declines, often trauma/pressure-triggered.
  • Recovery potential: Hearing loss is generally irreversible; cochlear implantation restores functional hearing in severe-to-profound cases with generally favorable outcomes in genetic/SLC26A4 etiologies.
  • Prognostic factors: Genotype class (M2 more severe than M1+CEVA); early identification and intervention improve language/communication outcomes; laterality (unilateral vs bilateral) does NOT predict hearing-loss severity — audiological measures (PTA, SRT, WRS) and VA width/operculum size did not differ significantly (p = 0.281–0.933; SRT p = 0.925; WRS p = 0.521) between unilateral and bilateral EVA.

Section 12 — Treatment

Current standard (supportive/symptomatic). - Hearing rehabilitation: hearing aids; cochlear implantation (CI) for severe-to-profound loss (NCIT: Cochlear Implant Procedure). SLC26A4/Pendred is a favorable CI genotype. - Thyroid management: levothyroxine for hypothyroidism (NCIT: Levothyroxine Sodium); monitor goiter; thyroidectomy only for compressive/nodular indications (NCIT: Thyroidectomy). - Preventive counseling: avoid head trauma/barotrauma; helmet use; caution with contact sports/diving. - Genetic counseling for families.

Emerging / preclinical disease-modifying strategies (not yet clinical).

Strategy Key result Model PMID
AAV gene replacement (AAV.Anc80L65-SLC26A4) delivered postnatally to endolymphatic sac + cochlear lateral wall Lower ABR thresholds; preserved hair cells; reduced ES enlargement; partial endocochlear-potential restoration; durable to adulthood Mouse 41701544
Small-molecule pendrin corrector (PC2-1) (HTS of 54,000 compounds) ↑ surface expression + anion-exchange activity of H723R; active in patient nasal epithelium; non-toxic; reaches µM cochlear perilymph In vitro / cell 37690388
CRISPR/Cas9 exon skipping Restores function for premature-termination c.919-2A>G allele DFNB4 mouse 39232211
Prenatal electroporation gene transfer Restored hearing + vestibular function Slc26a4-KO mouse 31784581

Pharmacogenomics / personalized medicine: correctors are genotype-specific (e.g., PC2-1 for the H723R misfolding class), while gene replacement/editing addresses null/splice alleles — a clear precision-medicine framework once a therapeutic window is respected.

"AAV.Anc80L65-mediated SLC26A4 delivery significantly improved hearing … preserved hair cells, reduced endolymphatic sac enlargement, partially restored the endocochlear potential, and mitigated inner ear structural degeneration." — PMID: 41701544. "pendrin corrector (PC2-1) increased the surface expression and anion exchange activity of p.H723R pendrin (H723R-PDS), the most prevalent genetic variant that causes Pendred syndrome and DFNB4." — PMID: 37690388.

Section 13 — Prevention

  • Primary prevention: Not preventable (Mendelian). Genetic/reproductive counseling, carrier screening in founder/consanguineous populations, and prenatal/preimplantation genetic diagnosis where the familial genotype is known.
  • Secondary prevention (early detection): newborn + serial childhood hearing screening (given later-onset risk); early audiologic/imaging work-up; thyroid monitoring for goiter/hypothyroidism.
  • Tertiary prevention (complication limitation): timely hearing aids/CI to prevent language/communication deficits; levothyroxine to prevent hypothyroid sequelae; trauma/pressure avoidance to reduce sudden hearing drops; balance rehabilitation.
  • Immunization / public-health / environmental: not applicable (non-infectious). Adequate dietary iodine supports thyroid function.

Section 14 — Other Species / Natural Disease

  • Taxonomy / orthologs: SLC26A4 is conserved across mammals; the mouse ortholog is Slc26a4 (Mus musculus, NCBI Taxon 10090). The SLC26/SulP family is deeply conserved (bacterial SulP transporters, anti-sigma factor antagonists share the STAS fold).
  • Natural disease in other species: No well-established spontaneous Pendred-equivalent companion-animal disease is documented; the primary comparative knowledge comes from engineered rodent models rather than naturally occurring animal disease.
  • Comparative biology / conservation: The elevator-type transport mechanism, the essential anion-binding basic residue, and the STAS domain are evolutionarily conserved, so disease mechanisms translate well between mouse and human — the basis for the strong predictive value of mouse models.
  • Zoonotic potential: None (genetic disorder).

Section 15 — Model Organisms

  • Principal model: Mouse (Mus musculus).
  • Slc26a4-null (knockout): profoundly deaf with severe inner-ear malformation and enlarged endolymphatic compartment — recapitulates severe human phenotype.
  • Inducible/temporal transgenic (doxycycline-controlled Slc26a4 on null background): defined the E16.5–P2 critical window; partial induction reproduces a human EVA-like partial hearing loss (PMID: 21965328).
  • Slc26a4(loop/loop) missense mutant: profoundly deaf with normal-sized thyroid (DFNB4-like) but atrophic thyroid microfollicles and cochlear-hypothyroidism-like inner-ear defects (PMID: 24760582); a related Slc26a4 missense mutant models otoconial/vestibular defects and BPPV predisposition (PMID: 31898392).
  • Model types available: knockout, knock-in/missense, conditional/inducible transgenic; CRISPR-edited allele-specific models (e.g., c.919-2A>G exon-skipping model).
  • In vitro/cellular models: heterologous cells expressing mutant pendrin (iodide-influx/surface-expression assays); patient-derived nasal epithelial cells for corrector testing.
  • Phenotype recapitulation: Strong for deafness, EVA/endolymphatic enlargement, endocochlear-potential loss, thyroid microfollicular defects, and therapeutic response.
  • Limitations: Mouse thyroid phenotype is often milder than human goiter; developmental timing differs (human critical window is prenatal, complicating direct translation of postnatal mouse therapy timing); strain-background effects on vestibular phenotypes.
  • Resources: MGI (Slc26a4), IMPC/IMSR for alleles.

Evidence Base (Key Literature)

PMID Title (abbrev.) Contribution
40956475 Pendrin defects in Sudanese CH families Inheritance, gene, cardinal features, prevalence 7.5–10/100,000
34345941 SLC26A4-related hearing loss genetic architecture M2/M1-CEVA/M0 classes; organification defect distinguishes PDS from DFNB4
22116353 Transcriptional regulation of pendrin Pendrin transport function + tissue distribution
35227018 CFTR–pendrin interplay Apical localization; CFTR partnership
21965328 Temporal Slc26a4 mouse model E16.5–P2 critical window; endolymph acidification / EP loss
24760582 Atrophic follicles / cochlear-hypothyroidism Thyroid-hormone-dependent inner-ear component
41066100 Reevaluation of EVA (n=2774) 95.9% biallelic; CNV/deep-intronic alleles; vertigo/goiter frequencies
23705809 Okinawa EVA/PDS Founder alleles H723R, IVS15+5G>A
41701544 Postnatal AAV Slc26a4 therapy Gene-replacement rescue + therapeutic window
37690388 Pendrin corrector PC2-1 Small-molecule chaperone for H723R
39232211 CRISPR exon skipping (DFNB4) Editing rescue for c.919-2A>G
31784581 Prenatal electroporation gene transfer Restored hearing/vestibular function
38582450 SLC26 molecular principles Anion-binding residue essential for antiport
22116355 STAS domain structure/function STAS → membrane targeting; disease mutations
38184688 Pendrin anion-exchange/inhibition Structural mechanism of exchange & inhibition
30634102 Unilateral vs bilateral EVA Laterality does not predict severity
40426046 Genetic heterogeneity in EVA/PDS Functional validation of novel variants
37668839 CHD7 variants in EVA Genetic heterogeneity beyond SLC26A4
38877731 Intrafamilial variability Variable expressivity with identical genotype

All statistical claims in Sections 1–12 are anchored to the verified abstract quotes reproduced inline above.

Mechanistic Model / Interpretation (Synthesis)

Pendred syndrome is best understood as a single-protein, multi-epithelium anion-transport disease whose phenotype is dictated by where and when pendrin function is lost:

  1. Inner ear (developmental, time-critical): Absence of pendrin-mediated HCO₃⁻ secretion during the perinatal window acidifies endolymph, collapses the endocochlear potential, and enlarges the endolymphatic compartment (EVA). A second, thyroid-hormone-dependent axis (local cochlear hypothyroidism) compounds the sensory deficit. Because the injury is developmental and window-bounded, hearing loss is largely fixed by early life yet clinically progressive/fluctuating — and, crucially, reversible only if intervention occurs within the window, which is why gene/pharmacologic rescue works in neonatal mice.
  2. Thyroid (metabolic, iodine-sensitive): Loss of apical iodide efflux impairs organification → compensatory goiter, penetrance modulated by iodine intake.
  3. Genotype grades severity (M2 > M1+CEVA > M0), and structure explains variant behavior: anion-binding/gate mutations kill transport, whereas trafficking mutants (H723R) are correctable by chaperones.

This model unifies the epidemiology, the imaging criteria, the founder genetics, and the therapeutic landscape into one coherent causal chain from SLC26A4 loss-of-function → epithelial anion-transport failure → organ-specific developmental/metabolic injury → clinical triad.

Limitations and Knowledge Gaps

  • Translational timing: The human hearing-critical window is prenatal; the postnatal success of mouse gene therapy may not map directly onto a treatable postnatal window in humans. Defining the human window is a central open question.
  • M0/M1 etiology: ~50% of European EVA lacks biallelic SLC26A4; the full genetic/regulatory architecture (CEVA mechanism, CHD7, FOXI1, KCNJ10, deep-intronic/CNV alleles) is incompletely resolved.
  • Genotype–phenotype variability: Marked intrafamilial variability (identical genotype, divergent inner-ear morphology) implies unidentified modifiers or stochastic developmental effects.
  • Thyroid phenotype quantification: Goiter penetrance and its iodine dependence are not precisely quantified across populations; mouse thyroid phenotype under-represents human goiter.
  • No human therapeutic trials yet: All disease-modifying approaches remain preclinical; safety, durability, delivery, and correct-window delivery are unproven in patients.
  • Vestibular burden under-studied: Vertigo is common (~43%) but its natural history and QoL impact are less characterized than hearing loss.

Proposed Follow-up Experiments / Actions

  1. Define the human therapeutic window via natural-history imaging/audiology cohorts and, where feasible, fetal inner-ear developmental staging, to determine whether prenatal or early-postnatal intervention is required.
  2. Advance genotype-tailored therapeutics: progress AAV SLC26A4 replacement toward IND-enabling studies for null/splice alleles; optimize/expand pendrin correctors beyond H723R to other misfolding-class variants; validate CRISPR exon-skipping for recurrent splice alleles (c.919-2A>G, IVS15+5G>A).
  3. Resolve M0/M1 cases with genome sequencing + RNA-seq (splicing), systematic CEVA and CNV screening, and CHD7/FOXI1/KCNJ10 analysis; build a curated functional-variant database with standardized iodide-influx/surface-expression assays.
  4. Population carrier screening in founder/consanguineous populations (Okinawa, Sudan, Iran, Pakistan) to enable cascade testing and reproductive counseling.
  5. Prospective vestibular + QoL study using validated instruments (e.g., SF-36/PROMIS, dizziness handicap inventory) stratified by genotype and laterality.
  6. Iodine-status intervention analysis to quantify how dietary iodine modifies goiter penetrance and hearing trajectory.
  7. Ontology curation for the knowledge base using the suggested HPO/GO/CL/UBERON/NCIT/CHEBI terms embedded above.

Report compiled from aggregated disease-level literature across 5 investigation iterations (38 papers reviewed, 9 confirmed findings). Evidence types: predominantly human clinical/genetic and mouse model-organism studies, with in-vitro functional and structural/computational support.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 23
Resolved 23
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 23
On topic 15
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 30
Resolved 28
Unresolved (possible confabulation) 1
Obsolete 1
Unverifiable 0
Terms whose name was checked 4
Terms named correctly 0
Terms named as a different term 4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0008550 (2 mentions) - the report calls it "MONDO"; MONDO calls it obsolete thoracolaryngopelvic dysplasia
  • HP:0011387 (1 mention) - the report calls it "Imaging manifestation"; HP calls it Enlarged vestibular aqueduct
  • HP:0011389 (1 mention) - the report calls it "inner ear malformation"; HP calls it Functional abnormality of the inner ear
  • HP:0031428 (1 mention) - the report calls it "abnormal thyroid physiology"; HP calls it Increased circulating osteocalcin level

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

  • CL:1000722 (1 mention) - CL does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

  • MONDO:0008550 (obsolete thoracolaryngopelvic dysplasia) (2 mentions) - replaced by MONDO:0008551